

HOSTED BY



ELSEVIER

Contents lists available at ScienceDirect

## Journal of Pharmacological Sciences

journal homepage: [www.elsevier.com/locate/jphs](http://www.elsevier.com/locate/jphs)

## Survey review

## Vascular nitric oxide: Beyond eNOS



Yingzi Zhao, Paul M. Vanhoutte, Susan W.S. Leung\*

State Key Laboratory of Pharmaceutical Biotechnology, Department of Pharmacology &amp; Pharmacy, The University of Hong Kong, Hong Kong SAR, China

## ARTICLE INFO

## Article history:

Received 28 August 2015

Received in revised form

11 September 2015

Accepted 16 September 2015

Available online 28 September 2015

## Keywords:

L-arginine

Endothelial cells

Nitric oxide

Nitric oxide synthase

Nitrate/nitrite

S-nitrosothiols

Vascular smooth muscle

## ABSTRACT

As the first discovered gaseous signaling molecule, nitric oxide (NO) affects a number of cellular processes, including those involving vascular cells. This brief review summarizes the contribution of NO to the regulation of vascular tone and its sources in the blood vessel wall. NO regulates the degree of contraction of vascular smooth muscle cells mainly by stimulating soluble guanylyl cyclase (sGC) to produce cyclic guanosine monophosphate (cGMP), although cGMP-independent signaling [S-nitrosylation of target proteins, activation of sarco/endoplasmic reticulum calcium ATPase (SERCA) or production of cyclic inosine monophosphate (cIMP)] also can be involved. In the blood vessel wall, NO is produced mainly from L-arginine by the enzyme endothelial nitric oxide synthase (eNOS) but it can also be released non-enzymatically from S-nitrosothiols or from nitrate/nitrite. Dysfunction in the production and/or the bioavailability of NO characterizes endothelial dysfunction, which is associated with cardiovascular diseases such as hypertension and atherosclerosis.

© 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological Society. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## 1. Introduction

Nitric oxide (NO) is a free radical (1), generated naturally by electrical discharges [e.g. lightning (2)], produced industrially as an important chemical intermediate (3), or released as an air pollutant from automobile engines or fossil fuel power plants (4, 5). Its potential endogenous production as an endothelium-derived relaxing factor (6) was first proposed independently by Robert Furchgott and Louis Ignarro in 1986 (7, 8) and confirmed in subsequent studies (9–12). It thus was the first gaseous molecule accepted to be a signaling mediator in the organism (13). It soon appeared that NO plays a key role in the physiological regulation of the cardiovascular system, since abnormalities in its productions and/or bioavailability accompany or even precede diseases such as hypertension, atherosclerosis and angiogenesis-associated disorders (14–17). NO also exerts physiological functions in the nervous and immune systems, contributing to the regulation of behavior, gastrointestinal motility, and defense mechanisms against infectious disease and tumors (18–24). This brief review focuses on the

sources of NO in the blood vessel wall and its role in the regulation of vascular tone.

## 2. Components of the vascular wall

Blood vessels are composed of three layers: an intimal monolayer of endothelial cells, medial vascular smooth muscle and the adventitia or tunica externa (Fig. 1) (25, 26).


The intimal monolayer of **endothelial cells** covers the entire vascular tree, from the heart to the smallest capillaries, thus forming the interior surface of all blood vessels, which functions a barrier between the blood in the lumen and the surrounding tissues (25). The endothelium plays a modulator role in the basal and dynamic regulation of blood vessel diameter by releasing endothelium-derived NO (Fig. 2) (6,27–30) and contracting prostanoids and peptides (31–38), and by initiating endothelium-dependent hyperpolarizations (39–44).

The **vascular smooth muscle** layer mediates the constriction and dilatation of the blood vessels (25). Contractions of vascular smooth muscle cells can be initiated by mechanical (intraluminal pressure, stretch) or pharmacological activation (i.e., by binding of ligands to cell surface receptors), which increase the intracellular calcium concentration either by release from internal stores (sarcoplasmic reticulum) or by influx into the cell following opening of calcium channels in the plasma membrane (Fig. 3) (45–52). The intracellular free calcium ions bind to calmodulin and

\* Corresponding author. State Key Laboratory of Pharmaceutical Biotechnology, Department of Pharmacology & Pharmacy, The University of Hong Kong, 2/F, Laboratory Block, Faculty of Medicine Building, Li Ka Shing Faculty of Medicine, 21 Sassoon Road, Hong Kong SAR, China. Tel.: +852 3917 9252.

E-mail address: [swsleung@hku.hk](mailto:swsleung@hku.hk) (S.W.S. Leung).


Peer review under responsibility of Japanese Pharmacological Society.



**Fig. 1. Structure of arterial wall.** The arterial wall is composed of three layers: tunica intima (endothelial cells and internal elastic membrane), tunica media (vascular smooth muscle cells and external elastic membrane), and tunica externa (adventitia; contains perivascular adipose tissue cells, fibroblast cells, collagen fibers and nerve endings).

the calcium-calmodulin complex activates myosin light chain kinase (MLCK). MLCK phosphorylates the myosin light chain (MLC), which leads to cross-bridge formation between the myosin heads and the actin filaments, resulting in contraction of the smooth muscle cells (Fig. 3) (53–59).

The **adventitia** (Fig. 1) contains nerve endings, perivascular adipose tissue (PVAT) and connective elements (fibroblasts and collagen fibers) that insure adherence to the surrounding organs. Components of the adventitia are also involved in vascular development and remodeling (60–64), immune surveillance and inflammatory cell trafficking (65–70), and signal exchanges between the blood vessel and the tissue in which it resides (60, 69, 71–74). In particular, the adipocytes of PVAT, like all fat cells, secrete adipokines which contribute to the regulation of vascular tone. For



**Fig. 3. Increased intracellular calcium stimulates contraction of vascular smooth muscle cells** 1. Mechanical or pharmacological activation increases the intracellular calcium ( $\text{Ca}^{2+}$ ) concentration either from internal stores (sarcoplasmic reticulum, SR) or by influx into the cell following opening of calcium channels in the plasma membrane; 2. The intracellular free calcium ions bind to calmodulin and the calcium-calmodulin complex activates myosin light chain kinase (MLCK); 3. Activated MLCK phosphorylates the myosin light chain (MLC), which leads to cross-bridge formation between the myosin heads and the actin filaments; 4. Cross-bridge formation results in contraction of the smooth muscle cell. Calcium channels: Receptor-operated channel (ROC); store-operated channel (SOC); voltage-dependent calcium channel (VDCC).  $\text{IP}_3\text{R}$ : inositol 1,4,5-trisphosphate ( $\text{IP}_3$ ) receptor-mediated calcium release. RyR: ryanodine receptor-mediated calcium release. MLCP: myosin light chain phosphatase.

example, in isolated rat aortic rings, the presence of PVAT decreases contractions to norepinephrine, an effect attributable to transferable vasodilator substances (75), termed “adipose-derived relaxing factors” (ADRF), which can cause direct relaxation of the vascular smooth muscle that they surround or, if and when they (e.g. adiponectin and angiotensin 1–7) reach endothelial cells, stimulate the production of NO (76–84). However, adipocytes also can produce adipokines (e.g. lipocalin-2) which can curtail this production (85, 86).


### 3. Sources of vascular nitric oxide

Although in the blood vessel wall NO is mainly produced from L-arginine by endothelial NOS (eNOS), other mechanisms of vascular NO production exist (87–90).


#### 3.1. L-arginine and nitric oxide synthases

L-arginine is the first discovered and best-characterized source of NO as substrate for NOS (10, 91–93). Three distinct genes encode NOS isozymes which catalyze the production of NO from L-arginine: neuronal NOS (nNOS or NOS-1), cytokine-inducible NOS (iNOS or NOS-2) and endothelial NOS (eNOS or NOS-3) (89, 94, 95). Triple NOSs null mice exhibit reduced endothelium-dependent relaxations (due mainly to blunted endothelium-dependent hyperpolarizations) and have a shorter life expectancy with accelerated appearance of cardiovascular diseases including hypertension, cardiac hypertrophy, diastolic heart failure, arteriosclerosis and myocardial infarction (96).

The production of NO from L-arginine by NOS requires the presence of various co-factors including tetrahydrobiopterin ( $\text{BH}_4$ ), flavin adenine dinucleotide, flavin mononucleotide, calmodulin and iron protoporphyrin IX (haeme) (94, 97). The three NOS isoforms are synthesized as monomers, and need to form dimers (Fig. 4) in order to bind  $\text{BH}_4$  and the substrate L-arginine to catalyze  $\text{NO}$  production (98). The monomers generate  $\text{O}_2^{\cdot -}$  instead of  $\text{NO}$  from their oxygenase domain; a condition which is referred to as



**Fig. 2. Endothelial nitric oxide synthase (eNOS) can be activated in calcium-dependent or -independent ways.** On the one hand, agonists, such as acetylcholine, bradykinin and histamine, act on specific receptors (R) on the endothelial cell membrane to increase the intracellular concentration of calcium, which binds to calmodulin (CaM) and leads to the activation of calmodulin-binding domain of eNOS to produce nitric oxide (NO). On the other hand, phosphorylation of eNOS independently of the calcium concentration is also important for the activation of the enzyme. Thr495 is an inhibitory site but Ser635 and Ser1179 are activation sites. The responses to hemodynamic shear stress and hormones are mediated mainly through this calcium-independent pathway.



**Fig. 4. Homodimers of nitric oxide synthase (NOS).** I, as monomers, NOS produce O<sub>2</sub><sup>-</sup> instead of NO<sup>-</sup>; II, even as homodimers, significant O<sub>2</sub><sup>-</sup> production will occur when the effective concentrations of L-arginine (L-Arg) falls below levels required to saturate the enzyme; III, when sufficient L-arginine and tetrahydrobiopterin (BH<sub>4</sub>) bind to coupled NOS, the electron flux provided by nicotinamide adenine dinucleotide phosphate (NADPH) passes through flavin adenine dinucleotide (FAD), flavin mononucleotide (FMN), calmodulin (CaM) and iron protoporphyrin IX (Haeme Fe), and is eventually used in NO production. BH<sub>4</sub> is essential for NOS coupling and reactive oxygen species (ROS) oxidize BH<sub>4</sub> to the BH<sub>3</sub> radical, leading to NOS uncoupling. The endogenous competitive inhibitor asymmetrical dimethyl arginine (ADMA) and arginase both reduce the L-arginine binding to NOS which decreases NO production.

NOS uncoupling (97). Compared to the actual protein presence of the NOS enzyme, its coupling is more important for the production of NO (99,100).

**Neuronal NOS** produces NO both in the central and peripheral nervous systems and thus plays a role in cell communication (19, 23, 24,101). NO produced by nNOS is implicated in the regulation of neuronal excitability and firing, in long-term potentiation or depression of synaptic plasticity, as well as in memory and learning processes. Moreover, NO produced by nNOS regulates the release of neurotransmitters such as acetylcholine, histamine and serotonin (102,103). Neuronal NOS is also expressed in cardiac and skeletal myocytes (104,105), smooth muscle and endothelial cells (106,107), the adventitial layer of penile arteries (108), and cells of macula densa in the kidney (109). A selective inhibitor of nNOS, S-methyl-L-thiocitrulline (SMTC), reduces the basal blood flow in the normal human forearm and coronary circulating, without affecting eNOS-mediated vasodilatation induced by acetylcholine or shear stress (110,111). *In vitro* experimental data implicates nNOS-derived NO in the local regulation of vascular tone independently of the central nervous system (112). Selective inhibition of nNOS by SMTC in explanted whole rat kidneys decreases afferent and efferent arteriolar diameters but does not affect vasodilatation in response to the endothelium-dependent vasodilator acetylcholine (113). Vinyl-L-N-5-(1-imino-3-butenyl)-L-ornithine (L-VNIO; another selective inhibitor of nNOS) increases the arterial vasoconstriction and local norepinephrine concentration in response to perivascular sympathetic nerve stimulation in mesenteric arteries (114). However, nNOS inhibition does not reduce the vasoconstriction to exogenous norepinephrine, indicating that nNOS-derived NO may affect neurotransmitter release from perivascular sympathetic nerves (114). Neuronal NOS also participates in neurogenic vasodilation in the rat skin microvasculature (115). NO produced by nNOS not only initiates but also participate in maintenance of penile erectile (108,116–119) and decreased expression of nNOS is found in patients with erectile dysfunction (120). In arteries of spontaneously hypertensive rats (SHR) but not in normotensive Wistar-Kyoto (WKY) rats, nNOS is expressed in the smooth muscle cells and its activation is stimulated by angiotensin II (106). Acute hypoxia

increases nNOS expression but reduces its activity due to substrate deprivation, whereas chronic hypoxia induces increased synthesis and activity of nNOS which attenuate hypoxia-induced vasoconstriction (121,122). Vascular injury induces expression of nNOS in the intima and the medial smooth muscle cells and selective inhibition of this isoform augments the responses to various vasoconstrictors, suppresses the production of cyclic guanosine monophosphate (cGMP), and exacerbates neointimal formation (123). Furthermore, the expression of vascular nNOS is also up-regulated by stimulation with angiotensin II, platelet-derived growth factor or statins (123–125).

The expression/presence of **inducible NOS** is minimal under physiological conditions. However, this isoform is calcium-insensitive and continuously produces NO once it is expressed (126). Induction of iNOS occurs mainly during infection, chronic inflammation and in tumors (127). The activation of iNOS promoter requires interferon regulatory factor 1 and nuclear factor K-light-chain-enhancer of activated B cells, explaining why expression of iNOS is characteristic of inflammation (128–136). Inflammation-induced iNOS expression in the endothelium but not in adventitia may contribute to vascular dysfunction by limiting the availability of BH<sub>4</sub> for eNOS (137). The production of iNOS within vascular smooth muscle cells following exposure to pro-inflammatory cytokines is a major cause of the hypotension, cardiodepression and vascular hyporeactivity in septic shock (138–142).

However, **eNOS** is the major isoform regulating vascular function (97,143). The activity of eNOS (Fig. 4), and thus the production of NO can be initiated/enhanced by several stimuli (Fig. 2) including shear stress (30,144–149), acetylcholine (150–153), bradykinin (154–157), histamine (158–162) and 17β-estradiol (163–167), in both calcium-dependent and -independent manners. Agonists, such as acetylcholine, bradykinin and histamine, act on specific receptors on the endothelial cell membrane to increase the intracellular concentration of calcium, which binds to calmodulin and leads to the activation of calmodulin-binding domain of eNOS (Fig. 4) (168–171). This facilitates electron flux from the reductase to the oxygenase domains of the enzyme for NO production (172). On the other hand, phosphorylation of eNOS independently of the



calcium concentration is also important for the activation of the enzyme because it facilitates the active flux of electrons from the reductase to the oxygenase domains (172). Phosphorylation is a post-translational modification, which adds a phosphate ( $\text{PO}_4^{3-}$ ) group to eNOS by kinases; the phosphate, in turn, is removed by phosphatases (173–177). This modification alters the activity of eNOS and different sites of phosphorylation can have opposing effects (178). Thus, for eNOS, Ser1177 (or Ser1179 depending on the species) is an activation site and Thr495 is an inhibitory site. Protein kinase A (PKA) and protein kinase B (Akt) activate eNOS by phosphorylating Ser1177 in response to various stimuli (149,174). By contrast, hydrogen peroxide and bradykinin activate eNOS to produce NO by elevating both Ser1177 phosphorylation and Thr495 dephosphorylation (179,180). Increases in NO release induced by increases in hemodynamic shear stress and  $17\beta$ -estradiol are mediated mainly through this calcium-independent pathway (149,163,168). In particular, shear stress induces phosphorylation of eNOS at Ser1179 and Ser635 in a PKA-dependent manner (144,181). In addition, herbal (e.g. aurantio-obtusin and puerarin) can regulate vascular tone by eNOS phosphorylation in an Akt-dependent manner (182,183).

### 3.2. S-nitrosothiols

S-nitrosothiols such as S-nitrosohemoglobin and S-nitrosoglutathione serve not only as downstream NO products regulating protein expression and function but also as sources of NO (87). In endothelial cells, S-nitrosothiols can be formed from exogenous S-nitrosothiol donors (i.e., S-nitrosoglutathione) or from endogenous NO produced by eNOS (184). In addition, NO groups can be transferred from a donor S-nitrosylated protein to an acceptor S-nitrosylation substrate in multi-protein complex situations (185). These S-nitrosothiols, with a half-life of around one hour, exist mainly in the mitochondria and peri-mitochondrial compartment of endothelial cells (184). There is also a circulating pool of S-nitrosoalbumin in the plasma whose levels are positively related to NOS activity. Thus, NOS inhibition results in a decrease of S-nitrosoalbumin but an increase of low-molecular-weight S-nitrosothiols such as S-nitrosoglutathione. S-nitrosoglutathione can transfer its NO group to the reactive thiols (cys $\beta$ 93) of hemoglobin, and the resulting S-nitrosohemoglobin can transfer the NO group to membrane-associated band 3 protein of erythrocytes; a process controlled by the oxygen level in the blood (186). S-nitrosothiols are stable compounds at 37 °C and pH 7.4 in the presence of transition metal ion chelators (187). The liberation of NO is promoted by trace amounts of transition metal ions ( $\text{Cu}^{2+}$  or  $\text{Fe}^{2+}$ ) (188), flash photolysis or by the combination of the two (189). Dithiothreitol (thiol-preserving agent) and vitamin C (antioxidant) stimulate NO release from S-nitrosothiols to induce capillary morphogenesis (190). By releasing NO, S-nitrosothiols are more powerful vasodilators than nitroglycerin and potent inhibitors of platelet aggregation; the latter can be achieved at lower concentrations than those required to elicit vasodilatations (191,192).


### 3.3. Nitrite and nitrate

Nitrite and nitrate are not only the products of the metabolism of NO but also act as a reservoir (87). Indeed, under certain conditions, different enzymes [hemoglobin, myoglobin, xanthine oxidoreductase, mitochondrial cytochrome oxidase, aldehyde dehydrogenase 2, cytochrome P450 reductase and cytochrome P450] can catalyze the reduction of nitrite or nitrate to generate NO.

Hemoglobin is an iron-containing protein in the red blood cells, which carries and transports oxygen in the circulation system (193–196). It is an oxygen sensor and produces NO from nitrite

under hypoxic conditions. Hypoxia causes a quaternary structural change in hemoglobin from oxyhemoglobin to deoxyhemoglobin. When hemoglobin is 40–60% saturated with oxygen and at pH 6.4, it generates NO from nitrite at a maximal rate (197). Myoglobin is also an iron- and oxygen-binding protein which is present in muscle cells. Deoxymyoglobin reduces nitrite to NO at a rate 36 times faster than deoxyhemoglobin *in vitro* (198). As oxygen sensors, hemoglobin and myoglobin shift from being NO scavengers to NO producers in hypoxia; this perception of decreased oxygen concentrations then, by releasing NO, induces vasodilatation and increases the blood supply to the hypoxic tissues (199–201). The enzyme xanthine oxidoreductase also produces NO from nitrate and nitrite in anoxic tissues; this mechanism protects against ischemia-reperfusion injury (202,203). Likewise, mitochondrial cytochrome c oxidase produces NO from nitrite in the mitochondria under hypoxic conditions; this NO production increases with decreasing pH (204). The production of NO by the latter two enzymes may be important for the redistribution of blood flow to ischemic tissue (204,205). By contrast, aldehyde dehydrogenase 2 (ALDH2) effectively converts organic nitrate compounds, such as nitroglycerin, to NO under normoxic conditions (206,207). Both cytosolic and mitochondrial ALDH2 can catalyze the bioactivation of exogenous nitroglycerin; however, an endogenous substrate for this enzyme has not been identified (206,207). The activity and expression of ALDH2 in the vascular system are reduced in the case of tolerance to organic nitrates (208,209).

Cytochrome P450 reductase and cytochrome P450 induce NO release by reducing nitrate and nitrite, respectively (210). Nitrate (transformed to NO by cytochrome P450 reductase) has been identified as another endothelial source of NOS-independent NO, which is only present in SHR arteries but not in those of normotensive WKY rats (Fig. 5) (90). Indeed, in the presence of NOS and cyclooxygenase inhibitors, in aortic rings with endothelium of SHR, but not of WKY, contractions to phenylephrine and prostaglandin  $\text{E}_2$  were smaller than in preparations without endothelium; this endothelium-dependent depression of contractions was abolished when the downstream NO signaling pathway was inhibited [by NO scavengers and inhibitors of soluble guanylyl cyclase (sGC)]. Such endothelium-dependent, eNOS-independent depression of contractions was larger in preparations of 36 than 18 weeks old SHR, thus suggesting that the chronic elevation in arterial blood pressure plays a role in the development of NOS-independent NO release (90). However, in the absence of cyclooxygenase inhibition, the




**Fig. 5. Nitric oxide ( $\text{NO}^-$ ) produce by cytochrome P450 reductase (CPR) from nitrate.** The endothelium-derived NO produced by CPR from nitrate is a supplement for NO produced by eNOS in arteries of the spontaneously hypertensive rat, and reduces the contractions to agonists. However, reactive oxygen species (ROS) significantly eliminate the NO production thus restoring the contractions.

endothelium-dependent, NOS-independent NO production was masked by reactive oxygen species (90), which supports the concept that oxidative stress play an important role in the endothelial dysfunction accompanying hypertension (211–215). The endothelium-dependent, cytochrome P450 reductase-mediated NO release from nitrate may serve as a compensatory mechanism to restore NO availability during endothelial dysfunction. Indeed, deficient production of NO by its canonical source (eNOS) is a feature of endothelial dysfunction associated with hypertension (216–219).

#### 4. Nitric oxide and vascular tone

Endothelium-derived NO is a powerful vasodilator (6–11). It stimulates soluble sGC in the vascular smooth muscle cells to induce formation of cGMP (12,220–223). Cyclic GMP activates protein kinase G, which promotes the reuptake of cytosolic calcium into the sarcoplasmic reticulum, the expulsion of calcium out of the cell, and the opening of calcium-activated potassium channels (Fig. 6) (224–228). The intracellular concentration of calcium decreases and MLCK can no longer phosphorylate myosin and relaxation of the smooth muscle cells ensues (Fig. 6) (49,229–232). In addition, NO can affect cellular activity independently of sGC-activation (233). Thus, NO stimulates the sarco/endoplasmic reticulum calcium ATPase (SERCA) reducing the intracellular calcium concentration and causing relaxation of the smooth muscle; NO-derived peroxynitrite (ONOO<sup>-</sup>) can directly enhance SERCA activity by S-glutathiolation (Fig. 6) (234). In the presence of an electron acceptor, NO reacts with the cysteine thiols to form S-nitrosylated proteins (235). Such S-nitrosylation reactions are specific in that not every cysteine-containing protein is S-nitrosylated and not



**Fig. 6. Regulation of vascular tone by nitric oxide (NO).** NO regulates vascular tone by three different signaling pathways. **I:** NO stimulates soluble guanylyl cyclase (sGC) in the vascular smooth muscle cells to induce formation of cyclic guanosine monophosphate (cGMP). Cyclic GMP activates protein kinase G (PKG), which prevents the calcium influx from voltage-dependent calcium channel (VDCC) and calcium release mediated by inositol 1,4,5-trisphosphate (IP<sub>3</sub>) receptor (IP<sub>3</sub>R). PKG also acts on sarco/endoplasmic reticulum calcium ATPase (SERCA) to promote the reuptake of cytosolic calcium into the sarcoplasmic reticulum (SR). The intracellular calcium concentration decreases and calmodulin is inactivated which no longer able to activate myosin light chain kinase (MLCK). Calcium depletion also increases the activity of myosin light chain phosphatase (MLCP). The actin-myosin cross-bridge is broken and smooth muscle relaxation ensues. **II:** under hypoxic condition, soluble guanylyl cyclase produces inosine cyclic 3',5'-monophosphate (cIMP) instead of cGMP, which activates Rho-associated protein kinase (ROCK) and inhibits MLCP, resulting in contraction. **III:** protein S-nitrosylated by NO. **IIIa:** S-nitrosylation increases the activity of SERCA which accelerates calcium depletion and induces relaxation. **IIIb:** G protein-coupled receptors (GPCR) can be directly S-nitrosylated by NO which impedes the binding of ligands for the receptor or G-protein coupling. **IIIc:** S-nitrosylation of G protein-coupled receptor kinase 2 (GRK2) prevents the desensitization and internalization of  $\beta$ -adrenoceptors. **IIId:** S-nitrosylation of  $\beta$ -arrestin 2 increases receptor internalization.

every cysteine residue in a protein becomes S-nitrosylated (185). Of particular importance for the tone of vascular smooth muscle, S-nitrosylation regulates the expression and functions of G protein-coupled receptors (GPCRs); this mechanism also plays a role in the regulation of vascular tone (185,236). For instance, NO and S-nitrosothiols modulate the activity of GPCR kinase 2 (GRK2) which phosphorylates  $\beta$ -adrenoceptors and induce receptor desensitization and internalization to curtail G-protein signaling. Thus, NO and S-nitrosothiols prevent the loss of  $\beta$ -adrenergic signaling *in vivo* by S-nitrosylating GRK2, attenuating GRK2-mediated phosphorylation of  $\beta$ -adrenoceptors and decreasing receptor desensitization and internalization (236,237). In the heart, activation of  $\beta_1$  and  $\beta_2$ -adrenoceptors increases heart rate and atrial cardiac muscle contractility (238–241); by contrast, activation of these receptors in blood vessels induces vasodilatation (242–244). Thus, increased NO production with greater S-nitrosylation of GRK2 (preventing the loss of  $\beta$ -adrenergic signaling) may increase cardiac output and improve perfusion of target organs. GPCRs also can be S-nitrosylated directly by chemical NO-donors; such S-nitrosylation of muscarinic (245) or bradykinin receptors (246) disrupts their coupling to G proteins. Likewise, S-nitrosoglutathione inhibits  $\alpha_1$ -adrenoceptor-mediated vasoconstriction and ligand binding (247). In addition, S-nitrosylation of cysteine 289 of the AT<sub>1</sub> receptor decreases its binding affinity for angiotensin II (248). Cytosolic  $\beta$ -arrestin binding to ligand-activated and GRK-phosphorylated GPCRs sterically impedes the interaction of G-proteins with activated GPCRs, resulting in GPCR signaling termination (249–251). Also,  $\beta$ -arrestin 2, can be S-nitrosylated on cysteine 410 by endogenous NO and S-nitrosoglutathione, which promotes binding of  $\beta$ -arrestin 2 to clathrin heavy chain/ $\beta$ -adaplin, thereby accelerating receptor internalization (252).

By contrast to its vasodilator effects, NO mediates hypoxic augmentation of contractions in coronary arteries, which is dependent on sGC but independent of cGMP (253,254): Indeed, acute hypoxia induces a transient further increase in tension in contracted coronary arterial rings, which can be abolished by L-NAME [L-N<sup>G</sup>-Nitroarginine methyl ester, NO synthase (NOS) inhibitor] or ODQ (1H-[1,2,4]Oxadiazolo[4,3-a]quinoxalin-1-one, sGC inhibitor) but is restored by the NO-donor DETA NONOate. However, the cGMP levels do not, but those of cyclic inosine monophosphate (cIMP) increase under these conditions and inhibitors of protein kinase G (the canonical target of cGMP) do not inhibit the hypoxic augmentation, indicating a novel, cIMP-mediated signaling mechanism for NO different from the classic NO-sGC-cGMP-relaxation pathway (Fig. 6) (253–256).

#### 5. NO deficiency

In patients with hypertension or prehypertension, and salt-sensitive hypertensive Dahl rats, the NO-mediated relaxation in response to acetylcholine is blunted (257–263). However, the relaxation of vascular smooth muscle to NO donors (such as sodium nitroprusside) is not altered (260–262,264,265). Thus, the reduced NO bioavailability can be attributed to a decreased NO production and/or an increased NO degradation. This conclusion is based on the evidence discussed in the following sections, taking mainly the SHR as an example of endothelial dysfunction.

##### 5.1. Decreased NO precursors

L-arginine, the precursor of NO, is an essential amino acid for young mammals. In healthy human adults, L-arginine can be synthesized from L-citrulline by endogenous (*de novo*) synthesis (266). Therefore, decreased availability of L-arginine and L-citrulline can contribute to NO deficiency (266–270). Even when the L-arginine

level is above the  $K_m$  [concentration of substrate that allows half maximal rate of the enzyme-mediated reaction] for NOS, reduced NO generation can occur; this can be due to decreased competitive displacement by the endogenous competitive inhibitor asymmetrical dimethyl arginine [ADMA (Fig. 4), which is a metabolic by-product created during protein methylation in the cytoplasm of all human cells (268,271–273)]. This is defined as the arginine paradox: the dependence of cellular NO production on the exogenous L-arginine concentration despite the theoretical saturation of NOS enzymes by intracellular L-arginine (268). The plasma level of L-arginine is not significantly different in SHR and WKY, but L-arginine metabolism is impaired in the former under stress conditions and by nifedipine (a dihydropyridine type calcium channel blocker) (274,275). Long-term L-arginine supplementation improves endothelial function of small coronary arteries and attenuates cardiac hypertrophy in the SHR (276,277). L-citrulline, the precursor of L-arginine, can dilate retinal arterioles through NO- and prostaglandin-dependent pathways without significantly changing arterial blood pressure, heart rate and fundus blood flow (278). On the other hand, elevated levels of arginase, which catalyzes the transformation of L-arginine to ornithine and urea, compete with NOS for the available L-arginine thus reducing the production of NO and increasing the release of  $O_2^{\cdot-}$  (279,280). Inhibition of arginase reduces blood pressure and improves vascular function in the SHR (281,282).

### 5.2. Impairment of NO synthesis

A decreased NO production could be due to reduced eNOS expression/presence in adult and old (around 36 and 72 weeks) SHR (36,283). However, endothelial dysfunction is associated with an increase rather than a decrease of eNOS expression (284–286). The up-regulated expression of eNOS in situations of endothelial dysfunction is likely to be the consequence of an elevated production of hydrogen peroxide, which is a dismutation product of  $O_2^{\cdot-}$ , and can increase the protein presence of eNOS by increasing the production and extending the half-life of its mRNA (287).

Uncoupling of eNOS has been reported in essential hypertensive patients with endothelial dysfunction (288), diabetes mellitus (289), or hypercholesterolemia (290) as well as in nitroglycerin-treated patients (291) and chronic smokers (292). In addition, eNOS uncoupling also can be observed in isolated blood vessels from animals with hypertension (99,100,293–295) or diabetes (296), and after induction of nitroglycerin tolerance (297). Several mechanisms contribute to the eNOS uncoupling causing endothelial dysfunction. Thus, vascular nicotinamide adenine dinucleotide phosphate-oxidase (NADPH oxidase) plays a crucial role in eNOS uncoupling, as it produces ROS, which leads to oxidation of the critical co-factor  $BH_4$  (298,299). Particularly, the direct reaction product of  $O_2^{\cdot-}$  and  $NO\cdot$ ,  $ONOO^-$ , also oxidizes  $BH_4$  to the  $BH_3$ -radical (Fig. 4) (300,301). This reaction can be reversed by vitamin C (302). Oxidative stress disrupts the balance between *de novo* synthesis of  $BH_4$  and its oxidation/degradation, thus leading to excessive depletion (303,304). For example, the  $BH_4$  level is reduced in the plasma of SHR compared to WKY rats (305), in the aorta of insulin-resistant rats (306), and in DOCA-salt-treated hypertensive rats (298).

### 5.3. Increased NO degradation

NO can undergo a number of reactions under biological conditions. It is spontaneously inactivated in the presence of oxygen or  $O_2^{\cdot-}$  (307,308). It also can be scavenged by oxyhemoglobin to yield methemoglobin and inorganic nitrate (309). In addition, NO reacts with thiol groups in proteins to yield S-nitrosothiols (235,310). The

presence of  $O_2^{\cdot-}$  causes rapid and nearly complete inactivation of endothelium-derived NO (311–314). ROS produced by cyclooxygenases also inactivate the NO produced by cytochrome P450 reductase in SHR arteries (90). The biological half-life of NO varies in function of the oxygen tension and the  $O_2^{\cdot-}$  concentration (313,315–318). In the concentration range of 10–50 nM, NO has a half-life of about three to five seconds; in concentrations in excess of 300 nM, its half-life is longer than 30 s (308). Thus, the accelerated degradation of NO can worsen its deficient production.

## 6. Conclusions

NO is a free radical which not only is present in the environment but also can be produced in the body as a vital signaling molecule. In the vasculature, NO stimulates sGC to produce cGMP, decreases the intracellular concentration of calcium, causes relaxation of vascular smooth muscle and thus is a potent vasodilator. Besides activating sGC, NO reacts with cysteine thiols to form S-nitrosylated proteins, which increase the activity of SERCA and reduce the intracellular concentration of free calcium ions, also facilitating relaxation. S-nitrosylation of GRK2 prevents  $\beta$ -adrenoceptor from desensitization and internalization, enhancing the vasodilator response to catecholamines. However, NO also mediates hypoxic augmentation of contraction in coronary arteries, a response which depends on sGC but is independent of cGMP production. NO can be produced from L-arginine, S-nitrosothiols and nitrate/nitrite in the vascular wall by different enzymes under different conditions. Endothelial dysfunction does not simply result from a decreased NO production by eNOS, but can also involve a complex combination of decreased availability of L-arginine, enzyme dysfunction and increased degradation. Thus, when analyzing the role of NO in the vascular wall, different signaling pathways and sources, and alterations in bioavailability should be considered.

## Conflicts of interest

The authors state no conflict of interest.

## References

- (1) Murad F. Discovery of some of the biological effects of nitric oxide and its role in cell signaling (Nobel lecture). *Angew Chem Int Ed.* 1999;38:1856–1868.
- (2) Goldenbaum G, Dickerson R. Nitric oxide production by lightning discharges. *J Geophys Res Atmos* (1984–2012). 1993;98:18333–18338.
- (3) Chen J, Yang R, Buzanowski M, Cichanowicz J. Cold selective catalytic reduction of nitric oxide for flue gas applications. *Industrial Eng Chem Res.* 1990;29:1431–1435.
- (4) EEA POPCE. Air Pollution from Electricity-generating Large Combustion Plants. EEA Technical Report. 2008. No 4, [www.eea.europa.eu/publications/technical\\_report\\_2008\\_4](http://www.eea.europa.eu/publications/technical_report_2008_4).
- (5) Faiz A, Weaver CS, Walsh MP. Air Pollution from Motor Vehicles: Standards and Technologies for Controlling Emissions. World Bank Publications; 1996.
- (6) Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. *Nature.* 1980;288:373–376.
- (7) Furchgott RF. Studies on Relaxation of Rabbit Aorta by Sodium Nitrite: The Basis for the Proposal that Acid-activable Inhibitory Factor from Bovine Retractor Penis Is Inorganic Nitrite and the Endothelium-derived Relaxing Factor Is Nitric Oxide. *Vasodilatation: Vascular Smooth Muscle Peptides, Autonomic Nerves and Endothelium.* In: Vanhoutte PM, editor. New York: Raven Press; 1988. p. 401–414.
- (8) Ignarro LJ, Byrns RE, Wood KS. Biochemical and Pharmacological Properties of Endothelium-Derived Relaxing Factor and its Similarity to Nitric Oxide Radical. *Vasodilatation: Vascular Smooth Muscle Peptides, Autonomic Nerves and Endothelium.* In: Vanhoutte PM, editor. New York: Raven Press; 1988. p. 427–436.
- (9) Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. *Nature.* 1987;327:524–526.
- (10) Palmer RM, Ashton D, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. *Nature.* 1988;333:664–666.



- (11) Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. *Proc Natl Acad Sci U S A*. 1987;84:9265–9269.
- (12) Furchgott RF, Vanhoutte PM. Endothelium-derived relaxing and contracting factors. *FASEB J*. 1989;3:2007–2018.
- (13) SoRelle R. Nobel prize awarded to scientists for nitric oxide discoveries. *Circulation*. 1998;98:2365–2366.
- (14) Moncada S, Higgs EA. Nitric oxide and the vascular endothelium. *Handb Exp Pharmacol* 2006;213–254.
- (15) Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. *Physiol Rev*. 2007;87:315–424.
- (16) Vanhoutte PM. How we learned to say NO. *Arterioscler Thromb Vasc Biol*. 2009;29:1156–1160.
- (17) Vanhoutte PM, Shimokawa H, Tang EH, Feletou M. Endothelial dysfunction and vascular disease. *Acta Physiol*. 2009;196:193–222.
- (18) Napoli C, Ignarro LJ. Nitric oxide and atherosclerosis. *Nitric Oxide*. 2001;5: 88–97.
- (19) Brett DS, Hwang PM, Snyder SH. Localization of nitric oxide synthase indicating a neural role for nitric oxide. *Nature*. 1990;347:768–770.
- (20) Hibbs Jr JB, Taintor RR, Vavrin Z, Rachlin EM. Nitric oxide: a cytotoxic activated macrophage effector molecule. *Biochem Biophys Res Commun*. 1988;157:87–94.
- (21) Brett DS, Snyder SH. Nitric oxide, a novel neuronal messenger. *Neuron*. 1992;8:3–11.
- (22) Bogdan C. Nitric oxide and the immune response. *Nat Immunol*. 2001;2: 907–916.
- (23) Toda N, Nakanishi-Toda M. How mental stress affects endothelial function. *Pflügers Archiv-European J Physiology*. 2011;462:779–794.
- (24) Toda N, Ayajiki K, Okamura T. Neurogenic and endothelial nitric oxide regulates blood circulation in lingual and other oral tissues. *J Cardiovasc Pharmacol*. 2012;60:100–108.
- (25) Shepherd JT, Vanhoutte PM. *The Human Cardiovascular System: Facts and Concepts*. 1979.
- (26) Aaronson PI, Ward JP, Connolly MJ. *The Cardiovascular System at a Glance*. Wiley-Blackwell; 2012.
- (27) Bauer V, Sotniková R. Nitric oxide—the endothelium-derived relaxing factor and its role in endothelial functions. *General Physiology Biophysics*. 2010;29:319–340.
- (28) Loscalzo J. The identification of nitric oxide as endothelium-derived relaxing factor. *Circulation Res*. 2013;113:100–103.
- (29) Furchgott RF. Endothelium-derived relaxing factor: discovery, early studies, and identification as nitric oxide. *Biosci Rep*. 1999;19:235–251.
- (30) Rubanyi GM, Romero JC, Vanhoutte PM. Flow-induced release of endothelium-derived relaxing factor. *Am J Physiology*. 1986;250: H1145–H1149.
- (31) Lüscher T, Vanhoutte PM. Endothelium-dependent contractions to acetylcholine in the aorta of the spontaneously hypertensive rat. *Hypertension*. 1986;8:344–348.
- (32) Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. *Nature*. 1988;332:411–415.
- (33) Tang EH, Ku DD, Tipoe GL, Feletou M, Man RY, Vanhoutte PM. Endothelium-dependent contractions occur in the aorta of wild-type and COX2-/- knockout but not COX1-/- knockout mice. *J Cardiovasc Pharmacol*. 2005;46: 761–765.
- (34) Tang EH, Feletou M, Huang Y, Man RY, Vanhoutte PM. Acetylcholine and sodium nitroprusside cause long-term inhibition of EDCF-mediated contractions. *Am J Physiology Heart Circulatory Physiology*. 2005;289: H2434–H2440.
- (35) Tang EH, Leung FP, Huang Y, Feletou M, So KF, Man RY, et al. Calcium and reactive oxygen species increase in endothelial cells in response to releasers of endothelium-derived contracting factor. *Br J Pharmacol*. 2007;151:15–23.
- (36) Tang EH, Vanhoutte PM. Gene expression changes of prostanoid synthases in endothelial cells and prostanoid receptors in vascular smooth muscle cells caused by aging and hypertension. *Physiol Genomics*. 2008;32:409–418.
- (37) Vanhoutte PM, Tang EH. Endothelium-dependent contractions: when a good guy turns bad! *J Physiology*. 2008;586:5295–5304.
- (38) Li Z, Wang Y, Vanhoutte PM. Upregulation of heme oxygenase 1 by hemin impairs endothelium-dependent contractions in the aorta of the spontaneously hypertensive rat. *Hypertension*. 2011;58:926–934.
- (39) Feletou M, Vanhoutte PM. Endothelium-dependent hyperpolarization of canine coronary smooth muscle. *Br J Pharmacol*. 1988;93:515–524.
- (40) Félétou M, Vanhoutte PM. Endothelium-derived hyperpolarizing factor where are we now? *Arterioscler Thromb Vasc Biol*. 2006;26:1215–1225.
- (41) Cohen RA, Vanhoutte PM. Endothelium-dependent hyperpolarization beyond nitric oxide and cyclic GMP. *Circulation*. 1995;92:3337–3349.
- (42) Mustafa AK, Sikka G, Gazi SK, Steppan J, Jung SM, Bhunia AK, et al. Hydrogen sulfide as endothelium-derived hyperpolarizing factor sulfhydrylates potassium channels. *Circulation Res*. 2011;109:1259–1268.
- (43) Edwards G, Félétou M, Weston AH. Hydrogen sulfide as an endothelium-derived hyperpolarizing factor in rodent mesenteric arteries. *Circulation Res*. 2012;110:e13–e14.
- (44) Li Z, Wang Y, Man RY, Vanhoutte PM. Upregulation of heme oxygenase-1 potentiates EDH-type relaxations in the mesenteric artery of the spontaneously hypertensive rat. *Am J Physiology-Heart Circulatory Physiology*. 2013;305:H1471–H1483.
- (45) Ji G, Barsotti RJ, Feldman ME, Kotlikoff MI. Stretch-induced calcium release in smooth muscle. *J General Physiology*. 2002;119:533–543.
- (46) Hilgers RH, Webb RC. Molecular aspects of arterial smooth muscle contraction: focus on Rho. *Exp Biol Med*. 2005;230:829–835.
- (47) Wiedeman MP. Contractile activity of arterioles in the bat wing during intraluminal pressure changes. *Circulation Res*. 1966;19:559–563.
- (48) Walsh MP. Vascular smooth muscle myosin light chain diphosphorylation: mechanism, function, and pathological implications. *IUBMB Life*. 2011;63: 987–1000.
- (49) Webb RC. Smooth muscle contraction and relaxation. *Adv Physiology Educ*. 2003;27:201–206.
- (50) Wray S, Burdyla T. Sarcoplasmic reticulum function in smooth muscle. *Physiol Rev*. 2010;90:113–178.
- (51) Devine CE, Somlyo AV, Somlyo AP. Sarcoplasmic reticulum and excitation-contraction coupling in mammalian smooth muscles. *J Cell Biol*. 1972;52: 690–718.
- (52) Cribbs LL. Vascular smooth muscle calcium channels could “T” be a target? *Circulation Res*. 2001;89:560–562.
- (53) Horowitz A, Menice CB, Laporte R, Morgan KG. Mechanisms of smooth muscle contraction. *Physiol Rev*. 1996;76:967–1003.
- (54) Shozo I, Potter JD. Calcium binding to calmodulin. Cooperativity of the calcium-binding sites. *J Biochem*. 1986;99:1765–1772.
- (55) Van Lierop JE, Wilson DP, Davis JP, Tikunova S, Sutherland C, Walsh MP, et al. Activation of smooth muscle myosin light chain kinase by calmodulin role of LYS30 and GLY40. *J Biol Chem*. 2002;277:6550–6558.
- (56) Raina H, Zacharia J, Li M, Wier W. Activation by Ca<sup>2+</sup>/calmodulin of an exogenous myosin light chain kinase in mouse arteries. *J Physiology*. 2009;587:2599–2612.
- (57) Walsh MP. Calmodulin and the regulation of smooth muscle contraction. *Mol Cell Biochem*. 1994;135:21–41.
- (58) Stull JT, Gallagher PJ, Herring BP, Kamm KE. Vascular smooth muscle contractile elements. Cellular regulation. *Hypertension*. 1991;17:723–732.
- (59) Rembold CM, Murphy RA. Models of the mechanism for crossbridge attachment in smooth muscle. *J Muscle Res Cell Motil*. 1993;14:325–334.
- (60) Haurani MJ, Pagano PJ. Adventitial fibroblast reactive oxygen species as autocrine and paracrine mediators of remodeling: bellwether for vascular disease? *Cardiovasc Res*. 2007;75:679–689.
- (61) Ruan C-C, Zhu D-L, Chen Q-Z, Chen J, Guo S-J, Li X-D, et al. Perivascular adipose tissue-derived complement 3 is required for adventitial fibroblast functions and adventitial remodeling in deoxycorticosterone acetate-salt hypertensive rats. *Arterioscler Thromb Vasc Biol*. 2010;30:2568–2574.
- (62) Miao CY, Li ZY. The role of perivascular adipose tissue in vascular smooth muscle cell growth. *Br J Pharmacol*. 2012;165:643–658.
- (63) Rey FE, Pagano PJ. The reactive adventitia fibroblast oxidase in vascular function. *Arterioscler Thromb Vasc Biol*. 2002;22:1962–1971.
- (64) Kwon HM, Sangiorgi G, Ritman EL, McKenna C, Holmes Jr DR, Schwartz RS, et al. Enhanced coronary vasa vasorum neovascularization in experimental hypercholesterolemia. *J Clin Investigation*. 1998;101:1551.
- (65) Galkina E, Kadl A, Sanders J, Varughese D, Sarembock IJ, Ley K. Lymphocyte recruitment into the aortic wall before and during development of atherosclerosis is partially L-selectin dependent. *J Exp Med*. 2006;203:1273–1282.
- (66) Tieu BC, Lee C, Sun H, Lejeune W, Recinos 3rd A, Ju X, et al. An adventitial IL-6/MCP1 amplification loop accelerates macrophage-mediated vascular inflammation leading to aortic dissection in mice. *J Clin Investigation*. 2009;119:3637.
- (67) Zhou J, Tang PC, Qin L, Gayed PM, Li W, Skokos EA, et al. CXCR3-dependent accumulation and activation of perivascular macrophages is necessary for homeostatic arterial remodeling to hemodynamic stresses. *J Exp Med*. 2010;207:1951–1966.
- (68) Swedenborg J, Mäyränpää MI, Kovanen PT. Mast cells important players in the orchestrated pathogenesis of abdominal aortic aneurysms. *Arterioscler Thromb Vasc Biol*. 2011;31:734–740.
- (69) Gräbner R, Lötzer K, Döpping S, Hildner M, Radke D, Beer M, et al. Lymphotoxin β receptor signaling promotes tertiary lymphoid organogenesis in the aorta adventitia of aged ApoE-/- mice. *J Exp Med*. 2009;206:233–248.
- (70) Campbell KA, Lipinski MJ, Doran AC, Skaffen MD, Fuster V, McNamara CA. Lymphocytes and the adventitial immune response in atherosclerosis. *Circulation Res*. 2012;110:889–900.
- (71) Majesky MW, Dong XR, Högglund V, Mahoney WM, Daum G. The adventitia a dynamic interface containing resident progenitor cells. *Arterioscler Thromb Vasc Biol*. 2011;31:1530–1539.
- (72) Gutterman DD. Adventitia-dependent influences on vascular function. *Am J Physiology-Heart Circulatory Physiology*. 1999;277:H1265–H1272.
- (73) Sartore S, Chiavegato A, Faggini E, Franch R, Puato M, Ausoni S, et al. Contribution of adventitial fibroblasts to neointima formation and vascular remodeling from innocent bystander to active participant. *Circulation Res*. 2001;89:1111–1121.
- (74) Gu P, Xu A. Interplay between adipose tissue and blood vessels in obesity and vascular dysfunction. *Rev Endocr Metabolic Disord*. 2013;14:49–58.
- (75) Soltis EE, Cassis LA. Influence of perivascular adipose tissue on rat aortic smooth muscle responsiveness. *Clin Exp Hypertens*. 1991;13:277–296.
- (76) Lee RM, Lu C, Su L-Y, Gao Y-J. Endothelium-dependent relaxation factor released by perivascular adipose tissue. *J Hypertens*. 2009;27:782–790.

- (77) Lee RM, Bader M, Alenina N, Santos RA, Gao Y-J, Lu C. Mas receptors in modulating relaxation induced by perivascular adipose tissue. *Life Sci*. 2011;89:467–472.
- (78) Lu C, Su L-Y, Lee RM, Gao Y-J. Alterations in perivascular adipose tissue structure and function in hypertension. *Eur J Pharmacol*. 2011;656:68–73.
- (79) Chen H, Montagnani M, Funahashi T, Shimomura I, Quon MJ. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. *J Biol Chem*. 2003;278:45021–45026.
- (80) Cheng KK, Lam KS, Wang Y, Huang Y, Carling D, Wu D, et al. Adiponectin-induced endothelial nitric oxide synthase activation and nitric oxide production are mediated by APPL1 in endothelial cells. *Diabetes*. 2007;56:1387–1394.
- (81) Fernández-Alfonso MS, Gil-Ortega M, García-Prieto CF, Arangué I, Ruiz-Gayo M, Somoza B. Mechanisms of perivascular adipose tissue dysfunction in obesity. *Int J Endocrinol*. 2013;2013.
- (82) Fésüs G, Dubrovská G, Gorzelniak K, Kluge R, Huang Y, Luft FC, et al. Adiponectin is a novel humoral vasodilator. *Cardiovasc Res*. 2007;75:719–727.
- (83) Greenstein AS, Khavandi K, Withers SB, Sonoyama K, Clancy O, Jeziorska M, et al. Local inflammation and hypoxia abolish the protective anticontractile properties of perivascular fat in obese patients. *Circulation*. 2009;119:1661–1670.
- (84) Li F, Cheng K, Lam K, Vanhoutte P, Xu A. Cross-talk between adipose tissue and vasculature: role of adiponectin. *Acta Physiol*. 2011;203:167–180.
- (85) Liang C-F, Liu JT, Wang Y, Xu A, Vanhoutte PM. Toll-like receptor 4 mutation protects obese mice against endothelial dysfunction by decreasing NADPH oxidase isoforms 1 and 4. *Arterioscler Thromb Vasc Biol*. 2013;33:777–784.
- (86) Song E, Fan P, Huang B, Deng HB, Cheung BM, Félétou M, et al. Deamidated lipocalin-2 induces endothelial dysfunction and hypertension in dietary obese mice. *J Am Heart Assoc*. 2014;3:e000837.
- (87) Chen K, Pittman RN, Popel AS. Nitric oxide in the vasculature: where does it come from and where does it go? A quantitative perspective. *Antioxidants Redox Signal*. 2008;10:1185–1198.
- (88) Zweier JL, Samouilov A, Kuppusamy P. Non-enzymatic nitric oxide synthesis in biological systems. *Biochim Biophys Acta*. 1999;1411:250–262.
- (89) Andrew PJ, Mayer B. Enzymatic function of nitric oxide synthases. *Cardiovasc Res*. 1999;43:521–531.
- (90) Zhao Y, Vanhoutte PM, Leung SW. Endothelial nitric oxide synthase-independent release of nitric oxide in the aorta of the spontaneously hypertensive rat. *J Pharmacol Exp Ther*. 2013;344:15–22.
- (91) Moncada S, Higgs A. The L-arginine-nitric oxide pathway. *N Engl J Med*. 1993;329:2002.
- (92) Schmidt HH, Klein MM, Niroomand F, Böhme E. Is arginine a physiological precursor of endothelium-derived nitric oxide? *Eur J Pharmacol*. 1988;148:293–295.
- (93) Sakuma I, Stuehr DJ, Gross SS, Nathan C, Levi R. Identification of arginine as a precursor of endothelium-derived relaxing factor. *Proc Natl Acad Sci*. 1988;85:8664–8667.
- (94) Alderton WK, Cooper CE, Knowles RG. Nitric oxide synthases: structure, function and inhibition. *Biochem J*. 2001;357:593–615.
- (95) Förstermann U, Sessa WC. Nitric oxide synthases: regulation and function. *Eur Heart J*. 2012;33:829–837.
- (96) Tsutsui M, Tanimoto A, Tamura M, Mukae H, Yanagihara N, Shimokawa H, et al. Significance of nitric oxide synthases: lessons from triple nitric oxide synthases null mice. *J Pharmacol Sci*. 2015;127:42–52.
- (97) Förstermann U, Munzel T. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. *Circulation*. 2006;113:1708–1714.
- (98) Rafikov R, Fonseca FV, Kumar S, Pardo D, Darragh C, Elms S, et al. eNOS activation and NO function: structural motifs responsible for the post-translational control of endothelial nitric oxide synthase activity. *J Endocrinol*. 2011;210:271–284.
- (99) Bhatt SR, Lokhandwala MF, Banday AA. Resveratrol prevents endothelial nitric oxide synthase uncoupling and attenuates development of hypertension in spontaneously hypertensive rats. *Eur J Pharmacol*. 2011;667:258–264.
- (100) Li H, Witte K, August M, Brausch I, Godtel-Armbrust U, Habermeier A, et al. Reversal of endothelial nitric oxide synthase uncoupling and up-regulation of endothelial nitric oxide synthase expression lowers blood pressure in hypertensive rats. *J Am Coll Cardiol*. 2006;47:2536–2544.
- (101) Dawson TM, Bredt DS, Fotuhi M, Hwang PM, Snyder SH. Nitric oxide synthase and neuronal NADPH diaphorase are identical in brain and peripheral tissues. *Proc Natl Acad Sci*. 1991;88:7797–7801.
- (102) Prast H, Philippu A. Nitric oxide as modulator of neuronal function. *Prog Neurobiol*. 2001;64:51–68.
- (103) Straub VA, Grant J, O'Shea M, Benjamin PR. Modulation of serotonergic neurotransmission by nitric oxide. *J Neurophysiology*. 2007;97:1088–1099.
- (104) Xu KY, Huso DL, Dawson TM, Bredt DS, Becker LC. Nitric oxide synthase in cardiac sarcoplasmic reticulum. *Proc Natl Acad Sci*. 1999;96:657–662.
- (105) Kobzik L, Reid MB, Bredt DS, Stamler JS. Nitric oxide in skeletal muscle. *Nature*. 1994;372:546–548.
- (106) Boulanger CM, Heymes C, Benessiano J, Geske RS, Lévy BI, Vanhoutte PM. Neuronal nitric oxide synthase is expressed in rat vascular smooth muscle cells activation by angiotensin II in hypertension. *Circulation Res*. 1998;83:1271–1278.
- (107) Bachetti T, Comini L, Curello S, Bastianon D, Palmieri M, Bresciani G, et al. Co-expression and modulation of neuronal and endothelial nitric oxide synthase in human endothelial cells. *J Mol Cell Cardiol*. 2004;37:939–945.
- (108) Burnett AL, Lowenstein CJ, Bredt DS, Chang T, Snyder SH. Nitric oxide: a physiologic mediator of penile erection. *Science*. 1992;257:401–403.
- (109) Bachmann S, Bosse HM, Mundel P. Topography of nitric oxide synthesis by localizing constitutive NO synthases in mammalian kidney. *Am J Physiology-Renal Physiology*. 1995;268:F885–F898.
- (110) Seddon MD, Chowienzyk PJ, Brett SE, Casadei B, Shah AM. Neuronal nitric oxide synthase regulates basal microvascular tone in humans in vivo. *Circulation*. 2008;117:1991–1996.
- (111) Seddon M, Melikian N, Dworakowski R, Shabeeh H, Jiang B, Byrne J, et al. Effects of neuronal nitric oxide synthase on human coronary artery diameter and blood flow in vivo. *Circulation*. 2009;119:2656–2662.
- (112) Melikian N, Seddon MD, Casadei B, Chowienzyk PJ, Shah AM. Neuronal nitric oxide synthase and human vascular regulation. *Trends Cardiovasc Med*. 2009;19:256–262.
- (113) Ichihara A, Inscho EW, Imig JD, Navar LG. Neuronal nitric oxide synthase modulates rat renal microvascular function. *Am J Physiology-Renal Physiology*. 1998;274:F516–F524.
- (114) Hatanaka Y, Hobara N, Honghua J, Akiyama S, Nawa H, Kobayashi Y, et al. Neuronal nitric-oxide synthase inhibition facilitates adrenergic neurotransmission in rat mesenteric resistance arteries. *J Pharmacol Exp Ther*. 2006;316:490–497.
- (115) Merhi M, Dusting GJ, Khalil Z. CGRP and nitric oxide of neuronal origin and their involvement in neurogenic vasodilatation in rat skin microvasculature. *Br J Pharmacol*. 1998;123:863–868.
- (116) Burnett AL. The role of nitric oxide in erectile dysfunction: implications for medical therapy. *J Clin Hypertens*. 2006;8:53–62.
- (117) Hurt KJ, Sezen SF, Lagoda GF, Musicki B, Rameau GA, Snyder SH, et al. Cyclic AMP-dependent phosphorylation of neuronal nitric oxide synthase mediates penile erection. *Proc Natl Acad Sci*. 2012;109:16624–16629.
- (118) Toda N, Okamura T. The pharmacology of nitric oxide in the peripheral nervous system of blood vessels. *Pharmacol Rev*. 2003;55:271–324.
- (119) Cashen DE, MacIntyre DE, Martin WJ. Effects of sildenafil on erectile activity in mice lacking neuronal or endothelial nitric oxide synthase. *Br J Pharmacol*. 2002;136:693–700.
- (120) R Dashwood M, Crump A, Shi-Wen X, Loesch A. Identification of neuronal nitric oxide synthase (nNOS) in human penis: a potential role of reduced neuronally-derived nitric oxide in erectile dysfunction. *Curr Pharm Biotechnol*. 2011;12:1316–1321.
- (121) Semenza GL. New insights into nNOS regulation of vascular homeostasis. *J Clin Investigation*. 2005;115:2976.
- (122) Ward ME, Toporsian M, Scott JA, Teoh H, Govindaraju V, Quan A, et al. Hypoxia induces a functionally significant and translationally efficient neuronal NO synthase mRNA variant. *J Clin Investigation*. 2005;115:3128.
- (123) Morishita T, Tsutsui M, Shimokawa H, Horiuchi M, Tanimoto A, Suda O, et al. Vasculoprotective roles of neuronal nitric oxide synthase. *FASEB J*. 2002;16:1994–1996.
- (124) Nakata S, Tsutsui M, Shimokawa H, Tamura M, Tasaki H, Morishita T, et al. Vascular neuronal NO synthase is selectively upregulated by platelet-derived growth factor involvement of the MEK/ERK pathway. *Arterioscler Thromb Vasc Biol*. 2005;25:2502–2508.
- (125) Nakata S, Tsutsui M, Shimokawa H, Yamashita T, Tanimoto A, Tasaki H, et al. Statin treatment upregulates vascular neuronal nitric oxide synthase through Akt/NF- $\kappa$ B pathway. *Arterioscler Thromb Vasc Biol*. 2007;27:92–98.
- (126) Gross SS, Jaffe EA, Levi R, Kilbourn RG. Cytokine-activated endothelial cells express an isotype of nitric oxide synthase which is tetrahydrobiopterin-dependent, calmodulin-independent and inhibited by arginine analogs with a rank-order of potency characteristic of activated macrophages. *Biochem Biophysical Res Commun*. 1991;178:823–829.
- (127) Kröncke K, Fehsel K, Kolb-Bachofen V. Inducible nitric oxide synthase in human diseases. *Clin Exp Immunol*. 1998;113:147–156.
- (128) Lowenstein CJ, Padalko E. iNOS (NOS2) at a glance. *J Cell Sci*. 2004;117:2865–2867.
- (129) Morris KR, Lutz RD, Choi HS, Kamitani T, Chmura K, Chan ED. Role of the NF-kappaB signaling pathway and kappaB cis-regulatory elements on the IRF-1 and iNOS promoter regions in mycobacterial lipaarabinomannan induction of nitric oxide. *Infect Immun*. 2003;71:1442–1452.
- (130) De Stefano D, Maiuri MC, Iovine B, Ialenti A, Bevilacqua MA, Carnuccio R. The role of NF-kappaB, IRF-1, and STAT-1alpha transcription factors in the iNOS gene induction by gliadin and IFN-gamma in RAW 264.7 macrophages. *J Mol Med*. 2006;84:65–74.
- (131) Kamijo R, Harada H, Matsuyama T, Bosland M, Gerecitano J, Shapiro D, et al. Requirement for transcription factor IRF-1 in NO synthase induction in macrophages. *Science*. 1994;263:1612–1615.
- (132) Flodström M, Eizirik DL. Interferon- $\gamma$ -induced interferon regulatory factor-1 (IRF-1) expression in rodent and human islet cells precedes nitric oxide production. *Endocrinology*. 1997;138:2747–2753.
- (133) Martin E, Nathan C, Xie Q. Role of interferon regulatory factor 1 in induction of nitric oxide synthase. *J Exp Med*. 1994;180:977–984.
- (134) Zamora R, Vodovotz Y, Billiar TR. Inducible nitric oxide synthase and inflammatory diseases. *Mol Med*. 2000;6:347.
- (135) Suschek CV, Schnorr O, Kolb-Bachofen V. The role of iNOS in chronic inflammatory processes in vivo: is it damage-promoting, protective, or active at all? *Curr Mol Med*. 2004;4:763–775.
- (136) Xie Q, Kashiwabara Y, Nathan C. Role of transcription factor NF-kappa B/Rel in induction of nitric oxide synthase. *J Biol Chem*. 1994;269:4705–4708.



- (137) Gunnnett C, Lund D, McDowell A, Faraci F, Heistad D. Mechanisms of inducible nitric oxide synthase-mediated vascular dysfunction. *Arterioscler Thromb Vasc Biol.* 2005;25:1617–1622.
- (138) Spink J, Cohen J, Evans TJ. The cytokine Responsive vascular smooth muscle cell enhancer of inducible nitric oxide synthase activation by nuclear factor- $\kappa$ B. *J Biol Chem.* 1995;270:29541–29547.
- (139) Kirkeboen K, Strand Ø. The role of nitric oxide in sepsis—an overview. *Acta Anaesthesiol Scand.* 1999;43:275–288.
- (140) MacMicking JD, Nathan C, Hom G, Chartrain N, Fletcher DS, Trumbauer M, et al. Altered responses to bacterial infection and endotoxic shock in mice lacking inducible nitric oxide synthase. *Cell.* 1995;81:641–650.
- (141) Sharshar T, Gray F, de la Grandmaison GL, Hopkinson NS, Ross E, Dorandeu A, et al. Apoptosis of neurons in cardiovascular autonomic centres triggered by inducible nitric oxide synthase after death from septic shock. *Lancet.* 2003;362:1799–1805.
- (142) Schini V, Junquero D, Scott-Burden T, Vanhoutte P. Interleukin-1  $\beta$  induces the production of an L-arginine-derived relaxing factor from cultured smooth muscle cells from rat aorta. *Biochem Biophysical Res Commun.* 1991;176:114–121.
- (143) Zhang Y, Janssens SP, Wingler K, Schmidt HH, Moens AL. Modulating endothelial nitric oxide synthase: a new cardiovascular therapeutic strategy. *Am J Physiology-Heart Circulatory Physiology.* 2011;301:H634–H646.
- (144) Boo YC, Sorescu G, Boyd N, Shiojima I, Walsh K, Du J, et al. Shear stress stimulates phosphorylation of endothelial nitric-oxide synthase at Ser1179 by Akt-independent mechanisms role of protein kinase A. *J Biol Chem.* 2002;277:3388–3396.
- (145) Xiao Z, Zhang Z, Diamond SL. Shear stress induction of the endothelial nitric oxide synthase gene is calcium-dependent but not calcium-activated. *J Cell Physiology.* 1997;171:205–211.
- (146) Kuchan MJ, Jo H, Frangos JA. Role of G proteins in shear stress-mediated nitric oxide production by endothelial cells. *Am J Physiology-Cell Physiology.* 1994;267:C753–C758.
- (147) Kolluru GK, Sinha S, Majumder S, Muley A, Siamwala JH, Gupta R, et al. Shear stress promotes nitric oxide production in endothelial cells by sub-cellular delocalization of eNOS: a basis for shear stress mediated angiogenesis. *Nitric Oxide.* 2010;22:304–315.
- (148) Andrews AM, Jaron D, Buerk DG, Kirby PL, Barbee KA. Direct, real-time measurement of shear stress-induced nitric oxide produced from endothelial cells in vitro. *Nitric Oxide.* 2010;23:335–342.
- (149) Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. *Nature.* 1999;399:601–605.
- (150) Kellogg D, Zhao J, Coey U, Green J. Acetylcholine-induced vasodilation is mediated by nitric oxide and prostaglandins in human skin. *J Appl Physiology.* 2005;98:629–632.
- (151) Xu Z, Tong C, Eisenach JC. Acetylcholine stimulates the release of nitric oxide from rat spinal cord. *Anesthesiology.* 1996;85:107–111.
- (152) Cohen RA, Plane F, Najibi S, Huk I, Malinski T, Garland CJ. Nitric oxide is the mediator of both endothelium-dependent relaxation and hyperpolarization of the rabbit carotid artery. *Proc Natl Acad Sci.* 1997;94:4193–4198.
- (153) Chen H-I, Chiang I-P, Jen C-J. Exercise training increases acetylcholine-stimulated endothelium-derived nitric oxide release in spontaneously hypertensive rats. *J Biomed Sci.* 1996;3:454–460.
- (154) Davissou RL, Bates JN, Johnson AK, Lewis SJ. Use-dependent loss of acetylcholine- and bradykinin-mediated vasodilation after nitric oxide synthase inhibition evidence for preformed stores of nitric oxide-containing factors in vascular endothelial cells. *Hypertension.* 1996;28:354–360.
- (155) Bae SW, Kim HS, Cha YN, Park YS, Jo SA, Jo I. Rapid increase in endothelial nitric oxide production by bradykinin is mediated by protein kinase A signaling pathway. *Biochem Biophysical Res Commun.* 2003;306:981–987.
- (156) Coppo R, Amore A. Importance of the bradykinin–nitric oxide synthase system in the hypersensitivity reactions of chronic haemodialysis patients. *Nephrol Dial Transplant.* 2000;15:1288–1290.
- (157) Danser AHJ, de Vries R, Schoemaker RG, Saxena PR. Bradykinin-induced release of nitric oxide by the isolated perfused rat heart: importance of preformed pools of nitric oxide-containing factors. *J Hypertens.* 1998;16:239–244.
- (158) Lantoin F, Iouzalen L, Devynck M, Millanvoye-Van Brussel E, David-Dufillo M. Nitric oxide production in human endothelial cells stimulated by histamine requires Ca<sup>2+</sup> influx. *Biochem J.* 1998;330:695–699.
- (159) Li H, Burkhardt C, Heinrich U-R, Brausch I, Xia N, Förstermann U. Histamine upregulates gene expression of endothelial nitric oxide synthase in human vascular endothelial cells. *Circulation.* 2003;107:2348–2354.
- (160) Kishi F, Nakaya Y, Ito S. Histamine H2-receptor-mediated nitric oxide release from porcine endothelial cells. *J Cardiovasc Pharmacol.* 1998;32:177–182.
- (161) Mondillo C, Pagotto RM, Piotrkowski B, Reche CG, Patrignani ZJ, Cymeryng CB, et al. Involvement of nitric oxide synthase in the mechanism of histamine-induced inhibition of Leydig cell steroidogenesis via histamine receptor subtypes in Sprague-Dawley rats. *Biol Reproduction.* 2009;80:144–152.
- (162) Mannaioni P, Bello M, Di Bello M, Mirabella C, Gai P, Schunack W, et al. Interaction between histamine and nitric oxide in rat mast cells and in isolated guinea pig hearts. *Int Archives Allergy Immunol.* 1997;113:297–299.
- (163) Caulin-Glaser T, Garcia-Cardena G, Sarrel P, Sessa WC, Bender JR. 17 $\beta$ -estradiol regulation of human endothelial cell basal nitric oxide release, independent of cytosolic Ca<sup>2+</sup> mobilization. *Circulation Res.* 1997;81:885–892.
- (164) Selles J, Polini N, Alvarez C, Massheimer V. Progesterone and 17  $\beta$ -estradiol acutely stimulate nitric oxide synthase activity in rat aorta and inhibit platelet aggregation. *Life Sci.* 2001;69:815–827.
- (165) Miyazaki-Akita A, Hayashi T, Ding QF, Shiraiishi H, Nomura T, Hattori Y, et al. 17 $\beta$ -Estradiol antagonizes the down-regulation of endothelial nitric-oxide synthase and GTP cyclohydrolase I by high glucose: relevance to postmenopausal diabetic cardiovascular disease. *J Pharmacol Exp Ther.* 2007;320:591–598.
- (166) Nekoeian AA, Lim SL, Man RY, Pang CC. Chronic 17 $\beta$ -estradiol augments relaxant role of basal nitric oxide in blood vessels from rats with heart failure. *Naunyn-Schmiedeberg's Archives Pharmacol.* 1998;358:671–677.
- (167) Chen Z, Yuhanna IS, Galcheva-Gargova Z, Karas RH, Mendelsohn ME, Shaul PW. Estrogen receptor  $\alpha$  mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen. *J Clin Investigation.* 1999;103:401.
- (168) Kuchan MJ, Frangos JA. Role of calcium and calmodulin in flow-induced nitric oxide production in endothelial cells. *Am J Physiology.* 1994;266:C628–C636.
- (169) Walch L, Brink C, Norel X. The muscarinic receptor subtypes in human blood vessels. *Therapie.* 2000;56:223–226.
- (170) Hall JM. Bradykinin receptors. *General Pharmacol Vasc Syst.* 1997;28:1–6.
- (171) Parsons ME, Ganellin CR. Histamine and its receptors. *Br J Pharmacol.* 2006;147:S127–S135.
- (172) Sessa WC. eNOS at a glance. *J Cell Sci.* 2004;117:2427–2429.
- (173) Butt E, Bernhardt M, Smolenski A, Kotsionis P, Fröhlich LG, Sickmann A, et al. Endothelial nitric-oxide synthase (type III) is activated and becomes calcium independent upon phosphorylation by cyclic nucleotide-dependent protein kinases. *J Biol Chem.* 2000;275:5179–5187.
- (174) Chen Z-P, Mitchellhill KI, Michell BJ, Stapleton D, Rodriguez-Crespo I, Witters LA, et al. AMP-activated protein kinase phosphorylation of endothelial NO synthase. *FEBS Lett.* 1999;443:285–289.
- (175) Fleming I, Fisslthaler B, Dimmeler S, Kemp BE, Busse R. Phosphorylation of Thr495 regulates Ca<sup>2+</sup>/calmodulin-dependent endothelial nitric oxide synthase activity. *Circulation Res.* 2001;88:e68–e75.
- (176) Michell B, Griffiths J, Mitchellhill K, Rodriguez-Crespo I, Tiganis T, Bozinovski S, et al. The Akt kinase signals directly to endothelial nitric oxide synthase. *Curr Biol.* 1999;9: S845–S841.
- (177) Greif DM, Kou R, Michel T. Site-specific dephosphorylation of endothelial nitric oxide synthase by protein phosphatase 2A: evidence for crosstalk between phosphorylation sites. *Biochemistry.* 2002;41:15845–15853.
- (178) Kolluru GK, Siamwala JH, Chatterjee S. eNOS phosphorylation in health and disease. *Biochimie.* 2010;92:1186–1198.
- (179) Harris MB, Ju H, Venema VJ, Liang H, Zou R, Michell BJ, et al. Reciprocal phosphorylation and regulation of endothelial nitric-oxide synthase in response to bradykinin stimulation. *J Biol Chem.* 2001;276:16587–16591.
- (180) Thomas SR, Chen K, Keaney JF. Hydrogen peroxide activates endothelial nitric-oxide synthase through coordinated phosphorylation and dephosphorylation via a phosphoinositide 3-kinase-dependent signaling pathway. *J Biol Chem.* 2002;277:6017–6024.
- (181) Boo YC, Hwang J, Sykes M, Michell BJ, Kemp BE, Lum H, et al. Shear stress stimulates phosphorylation of eNOS at Ser635 by a protein kinase A-dependent mechanism. *Am J Physiology-Heart Circulatory Physiology.* 2002;283:H1819–H1828.
- (182) Li S, Li Q, Lv X, Liao L, Yang W, Li S, et al. Auranthio-obtusin relaxes systemic arteries through endothelial PI3K/AKT/eNOS-dependent signaling pathway in rats. *J Pharmacol Sci.* 2015;128:108–115.
- (183) Zhang S-Y, Chen G, Wei P-F, Huang X-S, Dai Y, Shen Y-J, et al. The effect of puerarin on serum nitric oxide concentration and myocardial eNOS expression in rats with myocardial infarction. *J Asian Nat Prod Res.* 2008;10:323–328.
- (184) Yang Y, Loscalzo J. S-nitrosoprotein formation and localization in endothelial cells. *Proc Natl Acad Sci U S A.* 2005;102:117–122.
- (185) Daaka Y. S-nitrosylation-regulated GPCR signaling. *Biochim Biophys Acta.* 2012;1820:743–751.
- (186) Stamler JS. S-nitrosothiols in the blood: roles, amounts, and methods of analysis. *Circulation Res.* 2004;94:414–417.
- (187) Hogg N. Mechanism of nitric oxide release from S-nitrosothiols. *J Biol Chem.* 1996;271:18596–18603.
- (188) Askew SC, Barnett DJ, McAninly J, Williams DLH. Catalysis by Cu<sup>2+</sup> of nitric oxide release from S-nitrosothiols (RSNO). *J Chem Soc Perkin Trans.* 1995;2:741–745.
- (189) Rotta JC, Lunardi CN, Tedesco AC. Nitric oxide release from the S-nitrosothiol zinc phthalocyanine complex by flash photolysis. *Braz J Med Biol Res.* 2003;36:587–594.
- (190) Al-Ani B, Hewett PW, Ahmed S, Cudmore M, Fujisawa T, Ahmad S, et al. The release of nitric oxide from S-nitrosothiols promotes angiogenesis. *PLoS One.* 2006;1:e25.
- (191) Crane MS, Olsson R, Moore KP, Rossi AG, Megson IL. Novel role for low molecular weight plasma thiols in nitric oxide-mediated control of platelet function. *J Biol Chem.* 2002;277:46858–46863.

- (192) Langford E, Brown A, de Belder A, Smith R, Martin J, Wainwright R, et al. Inhibition of platelet activity by S-nitrosoglutathione during coronary angioplasty. *The Lancet*. 1994;344:1458–1460.
- (193) Weed RI, Reed CF, Berg G. Is hemoglobin an essential structural component of human erythrocyte membranes? *J Clin Invest*. 1963;42:581.
- (194) Doster W, Longeville S. Microscopic diffusion and hydrodynamic interactions of hemoglobin in red blood cells. *Biophys J*. 2007;93:1360–1368.
- (195) Dean L. *Blood Groups and Red Cell Antigens*. Bethesda (MD): National Center for Biotechnology Information (US); 2005.
- (196) Berg JM, Tymoczko JL, Stryer L. *Biochemistry*. fifth ed. New York: W H Freeman; 2002.
- (197) Huang Z, Shiva S, Kim-Shapiro DB, Patel RP, Ringwood LA, Irby CE, et al. Enzymatic function of hemoglobin as a nitrite reductase that produces NO under allosteric control. *J Clin Invest*. 2005;115:2099–2107.
- (198) Shiva S, Huang Z, Grubina R, Sun J, Ringwood LA, MacArthur PH, et al. Deoxyhemoglobin is a nitrite reductase that generates nitric oxide and regulates mitochondrial respiration. *Circ Res*. 2007;100:654–661.
- (199) Umbrello M, Dyson A, Feelisch M, Singer M. The key role of nitric oxide in hypoxia: hypoxic vasodilation and energy supply—demand matching. *Antioxid Redox Signal*. 2013;19:1690–1710.
- (200) Allen BW, Stamler JS, Piantadosi CA. Hemoglobin, nitric oxide and molecular mechanisms of hypoxic vasodilation. *Trends Mol Med*. 2009;15:452–460.
- (201) Flögel U, Fago A, Rassaf T. Keeping the heart in balance: the functional interactions of myoglobin with nitrogen oxides. *J Exp Biol*. 2010;213:2726–2733.
- (202) Li H, Samouilov A, Liu X, Zweier JL. Characterization of the magnitude and kinetics of xanthine oxidase-catalyzed nitrate reduction: evaluation of its role in nitrite and nitric oxide generation in anoxic tissues. *Biochemistry*. 2003;42:1150–1159.
- (203) Lu P, Liu F, Yao Z, Wang CY, Chen DD, Tian Y, et al. Nitrite-derived nitric oxide by xanthine oxidoreductase protects the liver against ischemia-reperfusion injury. *Hepatobiliary Pancreat Dis Int*. 2005;4:350–355.
- (204) Castello PR, David PS, McClure T, Crook Z, Poyton RO. Mitochondrial cytochrome oxidase produces nitric oxide under hypoxic conditions: implications for oxygen sensing and hypoxic signaling in eukaryotes. *Cell Metab*. 2006;3:277–287.
- (205) Zhang Z, Naughton D, Winyard PG, Benjamin N, Blake DR, Symons MC. Generation of nitric oxide by a nitrite reductase activity of xanthine oxidase: a potential pathway for nitric oxide formation in the absence of nitric oxide synthase activity. *Biochem Biophys Res Commun*. 1998;249:767–772.
- (206) Chen Z, Zhang J, Stamler JS. Identification of the enzymatic mechanism of nitroglycerin bioactivation. *Proc Natl Acad Sci U S A*. 2002;99:8306–8311.
- (207) Beretta M, Wolkart G, Schemthaler M, Griesberger M, Neubauer R, Schmidt K, et al. Vascular bioactivation of nitroglycerin is catalyzed by cytosolic aldehyde dehydrogenase-2. *Circ Res*. 2012;110:385–393.
- (208) Wölkart G, Beretta M, Wenzl M, Stessel H, Schmidt K, Maeda N, et al. Tolerance to nitroglycerin through proteasomal down-regulation of aldehyde dehydrogenase-2 in a genetic mouse model of ascorbate deficiency. *Br J Pharmacol*. 2013;168:1868–1877.
- (209) Sydow K, Daiber A, Oelze M, Chen Z, August M, Wendt M, et al. Central role of mitochondrial aldehyde dehydrogenase and reactive oxygen species in nitroglycerin tolerance and cross-tolerance. *J Clin Invest*. 2004;113:482.
- (210) Li H, Liu X, Cui H, Chen YR, Carouanel AJ, Zweier JL. Characterization of the mechanism of cytochrome P450 reductase-cytochrome P450-mediated nitric oxide and nitrosothiol generation from organic nitrates. *J Biol Chem*. 2006;281:12546–12554.
- (211) Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griending KK, et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. *J Clin Invest*. 1996;97:1916–1923.
- (212) Wind S, Beuerlein K, Armitage ME, Taye A, Kumar AH, Janowitz D, et al. Oxidative stress and endothelial dysfunction in aortas of aged spontaneously hypertensive rats by NOX1/2 is reversed by NADPH oxidase inhibition. *Hypertension*. 2010;56:490–497.
- (213) Gabrielli LA, Castro PF, Godoy I, Mellado R, Bourge RC, Alcaino H, et al. Systemic oxidative stress and endothelial dysfunction is associated with an attenuated acute vascular response to inhaled prostanoid in pulmonary artery hypertension patients. *J Card Fail*. 2011;17:1012–1017.
- (214) Schulz E, Gori T, Munzel T. Oxidative stress and endothelial dysfunction in hypertension. *Hypertens Res*. 2011;34:665–673.
- (215) Cuzzocrea S, Mazzon E, Dugo L, Di Paola R, Caputi AP, Salvemini D. Super-oxide: a key player in hypertension. *FASEB J*. 2004;18:94–101.
- (216) Thakali KM, Lau Y, Fink GD, Galligan JJ, Chen AF, Watts SW. Mechanisms of hypertension induced by nitric oxide (NO) deficiency: focus on venous function. *J Cardiovasc Pharmacol*. 2006;47:742–750.
- (217) Klinger JR, Abman SH, Gladwin MT. Nitric oxide deficiency and endothelial dysfunction in pulmonary arterial hypertension. *Am J Respir Crit Care Med*. 2013;188:639–646.
- (218) Tonelli AR, Haserodt S, Aytakin M, Dweik RA. Nitric oxide deficiency in pulmonary hypertension: pathobiology and implications for therapy. *Pulm Circ*. 2013;3:20.
- (219) Thomas GD, Zhang W, Victor RC. Nitric oxide deficiency as a cause of clinical hypertension: promising new drug targets for refractory hypertension. *JAMA*. 2001;285:2055–2057.
- (220) Arnold WP, Mittal CK, Katsuki S, Murad F. Nitric oxide activates guanylate cyclase and increases guanosine 3': 5'-cyclic monophosphate levels in various tissue preparations. *Proc Natl Acad Sci*. 1977;74:3203–3207.
- (221) Denninger JW, Marletta MA. Guanylate cyclase and the NO/cGMP signaling pathway. *Biochim Biophys Acta*. 1999;1411:334–350.
- (222) Hussain MB, Hobbs AJ, MacAllister RJ. Autoregulation of nitric oxide-soluble guanylate cyclase-cyclic GMP signalling in mouse thoracic aorta. *Br J Pharmacol*. 1999;128:1082–1088.
- (223) Derbyshire ER, Marletta MA. Structure and regulation of soluble guanylate cyclase. *Annu Rev Biochem*. 2012;81:533–559.
- (224) Carvajal JA, Germain AM, Huidobro-Toro JP, Weiner CP. Molecular mechanism of cGMP-mediated smooth muscle relaxation. *J Cell Physiol*. 2000;184:409–420.
- (225) Weisbrod RM, Griswold MC, Yaghoubi M, Komalavilas P, Lincoln TM, Cohen RA. Evidence that additional mechanisms to cyclic GMP mediate the decrease in intracellular calcium and relaxation of rabbit aortic smooth muscle to nitric oxide. *Br J Pharmacol*. 1998;125:1695–1707.
- (226) Cohen RA, Weisbrod RM, Gericke M, Yaghoubi M, Bieri C, Bolotina VM. Mechanism of nitric oxide-induced vasodilatation refilling of intracellular stores by sarcoplasmic reticulum Ca<sup>2+</sup> ATPase and inhibition of store-operated Ca<sup>2+</sup> influx. *Circ Res*. 1999;84:210–219.
- (227) Ignarro LJ, Kadowitz PJ. The pharmacological and physiological role of cyclic GMP in vascular smooth muscle relaxation. *Annu Rev Pharmacol Toxicol*. 1985;25:171–191.
- (228) Ledoux J, Werner ME, Brayden JE, Nelson MT. Calcium-activated potassium channels and the regulation of vascular tone. *Physiology*. 2006;21:69–78.
- (229) Mizuno Y, Isotani E, Huang J, Ding H, Stull JT, Kamm KE. Myosin light chain kinase activation and calcium sensitization in smooth muscle in vivo. *Am J Physiol Cell Physiol*. 2008;295:C358.
- (230) Lee MR, Li L, Kitazawa T. Cyclic GMP causes Ca<sup>2+</sup> desensitization in vascular smooth muscle by activating the myosin light chain phosphatase. *J Biol Chem*. 1997;272:5063–5068.
- (231) Lindpaintner K, Ganten D. *Molecular Reviews in Cardiovascular Medicine*. 1996.
- (232) Word RA, Tang D-C, Kamm KE. Activation properties of myosin light chain kinase during contraction/relaxation cycles of tonic and phasic smooth muscles. *J Biol Chem*. 1994;269:21596–21602.
- (233) Stamler JS, Simon DI, Osborne JA, Mullins ME, Jaraki O, Michel T, et al. S-nitrosylation of proteins with nitric oxide: synthesis and characterization of biologically active compounds. *Proc Natl Acad Sci*. 1992;89:444–448.
- (234) Adachi T, Weisbrod RM, Pimentel DR, Ying J, Sharov VS, Schöneich C, et al. S-Glutathionylation by peroxynitrite activates SERCA during arterial relaxation by nitric oxide. *Nat Med*. 2004;10:1200–1207.
- (235) Ignarro LJ, Lipperton H, Edwards JC, Baricos WH, Hyman AL, Kadowitz PJ, et al. Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: evidence for the involvement of S-nitrosothiols as active intermediates. *J Pharmacol Exp Ther*. 1981;218:739–749.
- (236) Whalen EJ, Foster MW, Matsumoto A, Ozawa K, Violin JD, Que LG, et al. Regulation of beta-adrenergic receptor signaling by S-nitrosylation of G-protein-coupled receptor kinase 2. *Cell*. 2007;129:511–522.
- (237) Whalen EJ, Johnson AK, Lewis SJ.  $\beta$ -adrenoceptor dysfunction after inhibition of NO synthesis. *Hypertension*. 2000;36:376–382.
- (238) Motomura S, Zerkowski H-R, Daul A, Brodde O-E. On the physiologic role of beta-2 adrenoceptors in the human heart: in vitro and in vivo studies. *Am Heart J*. 1990;119:608–619.
- (239) Brodde O-E. Beta-adrenoceptors in cardiac disease. *Pharmacol Ther*. 1993;60:405–430.
- (240) Bristow MR.  $\beta$ -Adrenergic receptor blockade in chronic heart failure. *Circulation*. 2000;101:558–569.
- (241) Lefkowitz RJ, Rockman HA, Koch WJ. Catecholamines, cardiac  $\beta$ -adrenergic receptors, and heart failure. *Circulation*. 2000;101:1634–1637.
- (242) Chruscinski A, Brede ME, Meinel L, Lohse MJ, Kobilka BK, Hein L. Differential distribution of  $\beta$ -adrenergic receptor subtypes in blood vessels of knockout mice lacking  $\beta$ 1- or  $\beta$ 2-adrenergic receptors. *Mol Pharmacol*. 2001;60:955–962.
- (243) Guimarães S, Moura D. Vascular adrenoceptors: an update. *Pharmacol Rev*. 2001;53:319–356.
- (244) Vatner DE, Knight DR, Homcy C, Vatner SF, Young MA. Subtypes of beta-adrenergic receptors in bovine coronary arteries. *Circ Res*. 1986;59:463–473.
- (245) Aronstam RS, Martin DC, Dennison RL, Cooley HG. S-Nitrosylation of m2 muscarinic receptor thiols disrupts Receptor-G-Protein Coupling. *Ann N Y Acad Sci*. 1995;757:215–217.
- (246) Miyamoto A, Laufs U, Pardo C, Liao JK. Modulation of bradykinin receptor ligand binding affinity and its coupled G-proteins by nitric oxide. *J Biol Chem*. 1997;272:19601–19608.
- (247) Nozik-Grayck E, Whalen EJ, Stamler JS, McMahon TJ, Chitano P, Piantadosi CA. S-nitrosoglutathione inhibits  $\alpha$ 1-adrenergic receptor-mediated vasoconstriction and ligand binding in pulmonary artery. *Am J Physiol Lung Cellular Mol Physiol*. 2006;290:L136–L143.
- (248) Leclerc PC, Lancot PM, Auger-Messier M, Escher E, Leduc R, Guillemette G. S-nitrosylation of cysteine 289 of the AT1 receptor decreases its binding affinity for angiotensin II. *Br J Pharmacol*. 2006;148:306–313.
- (249) Pierce KL, Premont RT, Lefkowitz RJ. Seven-transmembrane receptors. *Nat Rev Mol Cell Biol*. 2002;3:639–650.

- (250) Reiter E, Lefkowitz RJ. GRKs and beta-arrestins: roles in receptor silencing, trafficking and signaling. *Trends Endocrinol Metab.* 2006;17:159–165.
- (251) Pitcher JA, Freedman NJ, Lefkowitz RJ. G protein-coupled receptor kinases. *Annu Rev Biochem.* 1998;67:653–692.
- (252) Ozawa K, Whalen EJ, Nelson CD, Mu Y, Hess DT, Lefkowitz RJ, et al. S-nitrosylation of  $\beta$ -arrestin regulates  $\beta$ -adrenergic receptor trafficking. *Mol Cell.* 2008;31:395–405.
- (253) Chan CK, Mak J, Gao Y, Man RY, Vanhoutte PM. Endothelium-derived NO, but not cyclic GMP, is required for hypoxic augmentation in isolated porcine coronary arteries. *Am J Physiol Heart Circ Physiol.* 2011;301:H2313–H2321.
- (254) Chen Z, Zhang X, Ying L, Dou D, Li Y, Bai Y, et al. cIMP synthesized by sGC as a mediator of hypoxic contraction of coronary arteries. *Am J Physiol Heart Circ Physiol.* 2014;307:H328–H336.
- (255) Gao Y, Vanhoutte PM. Tissues cIMPly do not lie. *Naunyn-Schmiedeberg's Arch Pharmacol.* 2014;387:901–903.
- (256) Gao Y, Chen Z, Sws L, Vanhoutte PM. Hypoxic vasospasm mediated by cIMP: when soluble guanylyl cyclase turns bad. *J Cardiovasc Pharmacol.* 2014;10.
- (257) Lüscher T, Diederich D, Weber E, Vanhoutte PM, Bühler F. Endothelium-dependent responses in carotid and renal arteries of normotensive and hypertensive rats. *Hypertension.* 1988;11:573–578.
- (258) Linder L, Kiowski W, Buhler FR, Luscher TF. Indirect evidence for release of endothelium-derived relaxing factor in human forearm circulation in vivo. Blunted response in essential hypertension. *Circulation.* 1990;81:1762–1767.
- (259) Taddei S, Virdis A, Ghiadoni L, Magagna A, Salvetti A. Cyclooxygenase inhibition restores nitric oxide activity in essential hypertension. *Hypertension.* 1997;29:274–279.
- (260) Cardillo C, Kilcoyne CM, Cannon RO, Panza JA. Impairment of the nitric oxide-mediated vasodilator response to mental stress in hypertensive but not in hypercholesterolemic patients. *J Am Coll Cardiol.* 1998;32:1207–1213.
- (261) Higashi Y, Sasaki S, Nakagawa K, Matsuura H, Chayama K, Oshima T. Effect of obesity on endothelium-dependent, nitric oxide-mediated vasodilation in normotensive individuals and patients with essential hypertension. *Am J Hypertens.* 2001;14:1038–1045.
- (262) Weil BR, Stauffer BL, Greiner JJ, DeSouza CA. Prehypertension is associated with impaired nitric oxide-mediated endothelium-dependent vasodilation in sedentary adults. *Am J Hypertens.* 2011;24:976–981.
- (263) Giles TD, Sander GE, Nossaman BD, Kadowitz PJ. Impaired vasodilation in the pathogenesis of hypertension: focus on nitric oxide, endothelial-derived hyperpolarizing factors, and prostaglandins. *J Clin Hypertens.* 2012;14:198–205.
- (264) Intengan HD, Schiffrin EL. Vasopeptidase inhibition has potent effects on blood pressure and resistance arteries in stroke-prone spontaneously hypertensive rats. *Hypertension.* 2000;35:1221–1225.
- (265) Nunes VW, Fortes ZB, Nigro D, Carvalho MHC, Zorn TMT, Scivoletto R. Influence of enalapril on the endothelial function of DOCA-salt hypertensive rats. *Gen Pharmacol-Vasc S.* 2000;34:117–125.
- (266) El-Hattab AW, Emrick LT, Craigen WJ, Scaglia F. Citrulline and arginine utility in treating nitric oxide deficiency in mitochondrial disorders. *Mol Genet Metab.* 2012;107:247–252.
- (267) Yao XH, Lu XY, Zhang LZ, Niu DD, Gao LR, Pang YZ, et al. L-arginine transport in cultured vascular smooth muscle cells of spontaneously hypertensive rats and effect of liposome on the transport. *Sheng Li Xue Bao.* 1997;49:67–72.
- (268) Lee J, Ryu H, Ferrante RJ, Morris SM, Ratan RR. Translational control of inducible nitric oxide synthase expression by arginine can explain the arginine paradox. *Proc Natl Acad Sci.* 2003;100:4843–4848.
- (269) Moss MB, Brunini TM, Soares De Moura R, Novaes Malagris LE, Roberts NB, Ellory JC, et al. Diminished L-arginine bioavailability in hypertension. *Clin Sci.* 2004;107:391–397.
- (270) Getz GS, Reardon CA. Arginine/Arginase NO NO NO. *Arterioscler Thromb Vascular Biology.* 2006;26:237–239.
- (271) Boger RH, Bode-Boger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. *Circulation.* 1998;98:1842–1847.
- (272) Sibal L, Agarwal SC, Home PD, Boger RH. The role of asymmetric dimethylarginine (ADMA) in endothelial dysfunction and cardiovascular disease. *Curr Cardiol Rev.* 2010;6:82–90.
- (273) Tain YL, Huang LT, Lin IC, Lau YT, Lin CY. Melatonin prevents hypertension and increased asymmetric dimethylarginine in young spontaneous hypertensive rats. *J Pineal Res.* 2010;49:390–398.
- (274) Hasegawa T, Takagi S, Nishimaki K, Morita K, Nakajima S. Impairment of L-arginine metabolism in spontaneously hypertensive rats. *Biochem Int.* 1992;26:653–658.
- (275) Prados P, Matsunaga H, Mori T, Santa T, Fukushima T, Homma H, et al. Changes of plasma L-arginine levels in spontaneously hypertensive rats under induced hypotension. *Biomed Chromatogr.* 1999;13:27–32.
- (276) Matsuoka H, Nakata M, Kohno K, Koga Y, Nomura G, Toshima H, et al. Chronic L-arginine administration attenuates cardiac hypertrophy in spontaneously hypertensive rats. *Hypertension.* 1996;27:14–18.
- (277) Lerman A, Burnett Jr JC, Higano ST, McKinley LJ, Holmes Jr DR. Long-term L-arginine supplementation improves small-vessel coronary endothelial function in humans. *Circulation.* 1998;97:2123–2128.
- (278) Mori A, Morita M, Morishita K, Sakamoto K, Nakahara T, Ishii K. L-Citrulline dilates rat retinal arterioles via nitric oxide- and prostaglandin-dependent pathways in vivo. *J Pharmacol Sci.* 2015;127:419–423.
- (279) Chandra S, Romero MJ, Shatanawi A, Alkilany AM, Caldwell RB, Caldwell RW. Oxidative species increase arginase activity in endothelial cells through the RhoA/Rho kinase pathway. *Br J Pharmacol.* 2012;165:506–519.
- (280) Li H, Meiningner CJ, Hawker Jr JR, Haynes TE, Kepka-Lenhart D, Mistry SK, et al. Regulatory role of arginase I and II in nitric oxide, polyamine, and proline syntheses in endothelial cells. *Am J Physiol Endocrinol Metab.* 2001;280:E75–E82.
- (281) Demougeot C, Prigent-Tessier A, Marie C, Berthelot A. Arginase inhibition reduces endothelial dysfunction and blood pressure rising in spontaneously hypertensive rats. *J Hypertens.* 2005;23:971–978.
- (282) Bagnost T, Ma L, da Silva RF, Rezakhanliha R, Houdayer C, Stergiopoulos N, et al. Cardiovascular effects of arginase inhibition in spontaneously hypertensive rats with fully developed hypertension. *Cardiovasc Res.* 2010;87:569–577.
- (283) Chou TC, Yen MH, Li CY, Ding YA. Alterations of nitric oxide synthase expression with aging and hypertension in rats. *Hypertension.* 1998;31:643–648.
- (284) Vaziri ND, Ni Z, Oveysi F. Upregulation of renal and vascular nitric oxide synthase in young spontaneously hypertensive rats. *Hypertension.* 1998;31:1248–1254.
- (285) Li H, Wallerath T, Munzel T, Forstermann U. Regulation of endothelial-type NO synthase expression in pathophysiology and in response to drugs. *Nitric Oxide.* 2002;7:149–164.
- (286) Graham DA, Rush JW. Exercise training improves aortic endothelium-dependent vasorelaxation and determinants of nitric oxide bioavailability in spontaneously hypertensive rats. *J Appl Physiol.* 2004;96:2088–2096.
- (287) Drummond GR, Cai H, Davis ME, Ramasamy S, Harrison DG. Transcriptional and posttranscriptional regulation of endothelial nitric oxide synthase expression by hydrogen peroxide. *Circ Res.* 2000;86:347–354.
- (288) Higashi Y, Sasaki S, Nakagawa K, Fukuda Y, Matsuura H, Oshima T, et al. Tetrahydrobiopterin enhances forearm vascular response to acetylcholine in both normotensive and hypertensive individuals. *Am J Hypertens.* 2002;15:326–332.
- (289) Heitzer T, Krohn K, Albers S, Meinertz T. Tetrahydrobiopterin improves endothelium-dependent vasodilation by increasing nitric oxide activity in patients with type II diabetes mellitus. *Diabetologia.* 2000;43:1435–1438.
- (290) Stroes E, Kastelein J, Cosentino F, Erkelens W, Wever R, Koomans H, et al. Tetrahydrobiopterin restores endothelial function in hypercholesterolemia. *J Clin Invest.* 1997;99:41.
- (291) Gori T, Burstein JM, Ahmed S, Miner SE, Al-Hesayen A, Kelly S, et al. Folic acid prevents nitroglycerin-induced nitric oxide synthase dysfunction and nitrate tolerance: a human in vivo study. *Circulation.* 2001;104:1119–1123.
- (292) Heitzer T, Brockhoff C, Mayer B, Warnholtz A, Mollnau H, Henne S, et al. Tetrahydrobiopterin improves endothelium-dependent vasodilation in chronic smokers: evidence for a dysfunctional nitric oxide synthase. *Circ Res.* 2000;86:E36–E41.
- (293) Cosentino F, Lüscher TF. Tetrahydrobiopterin and endothelial function. *Eur Heart J.* 1998;19(Suppl. G):G3–G8.
- (294) Kerr S, Brosnan MJ, McIntyre M, Reid JL, Dominiczak AF, Hamilton CA. Superoxide anion production is increased in a model of genetic hypertension role of the endothelium. *Hypertension.* 1999;33:1353–1358.
- (295) Mollnau H, Wendt M, Szöcs K, Lassègue B, Schulz E, Oelze M, et al. Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. *Circ Res.* 2002;90:e58–e65.
- (296) Hink U, Li H, Mollnau H, Oelze M, Matheis E, Hartmann M, et al. Mechanisms underlying endothelial dysfunction in diabetes mellitus. *Circ Res.* 2001;88:E14–E22.
- (297) Munzel T, Li H, Mollnau H, Hink U, Matheis E, Hartmann M, et al. Effects of long-term nitroglycerin treatment on endothelial nitric oxide synthase (NOS III) gene expression, NOS III-mediated superoxide production, and vascular NO bioavailability. *Circ Res.* 2000;86:E7–E12.
- (298) Landmesser U, Dikalov S, Price SR, McCann L, Fukai T, Holland SM, et al. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. *J Clin Invest.* 2003;111:1201–1209.
- (299) Paravcinini TM, Touyz RM. NADPH oxidases, reactive oxygen species, and hypertension: clinical implications and therapeutic possibilities. *Diabetes Care.* 2008;31(Suppl. 2):S170–S180.
- (300) Werner ER, Gorren AC, Heller R, Werner-Felmayer G, Mayer B. Tetrahydrobiopterin and nitric oxide: mechanistic and pharmacological aspects. *Exp Biol Med.* 2003;228:1291–1302.
- (301) Kietadisorn R, Juni RP, Moens AL. Tackling endothelial dysfunction by modulating NOS uncoupling: new insights into its pathogenesis and therapeutic possibilities. *Am J Physiol Endocrinol Metab.* 2012;302:E481–E495.
- (302) Kuzkaya N, Weissmann N, Harrison DG, Dikalov S. Interactions of peroxynitrite, tetrahydrobiopterin, ascorbic acid, and thiols: implications for uncoupling endothelial nitric-oxide synthase. *J Biol Chem.* 2003;278:22546–22554.
- (303) Milstien S, Katusic Z. Oxidation of tetrahydrobiopterin by peroxynitrite: implications for vascular endothelial function. *Biochem Biophys Res Commun.* 1999;263:681–684.
- (304) Laursen JB, Somers M, Kurz S, McCann L, Warnholtz A, Freeman BA, et al. Endothelial regulation of vasomotion in apoE-deficient mice implications for



- interactions between peroxynitrite and tetrahydrobiopterin. *Circulation*. 2001;103:1282–1288.
- (305) Hong H-J, Hsiao G, Cheng T-H, Yen M-H. Supplementation with tetrahydrobiopterin suppresses the development of hypertension in spontaneously hypertensive rats. *Hypertension*. 2001;38:1044–1048.
- (306) Shinozaki K, Kashiwagi A, Nishio Y, Okamura T, Yoshida Y, Masada M, et al. Abnormal biopterin metabolism is a major cause of impaired endothelium-dependent relaxation through nitric oxide/O<sub>2</sub>-imbalance in insulin-resistant rat aorta. *Diabetes*. 1999;48:2437–2445.
- (307) Blough NV, Zafiriou OC. Reaction of superoxide with nitric oxide to form peroxynitrite in alkaline aqueous solution. *Inorg Chem*. 1985;24:3502–3504.
- (308) Ignarro LJ. Biosynthesis and metabolism of endothelium-derived nitric oxide. *Annu Rev Pharmacol Toxicol*. 1990;30:535–560.
- (309) Kelm M, Feelisch M, Spahr R, Piper H-M, Noack E, Schrader J. Quantitative and kinetic characterization of nitric oxide and EDRF released from cultured endothelial cells. *Biochem Biophys Res Commun*. 1988;154:236–244.
- (310) Saville B. A scheme for the colorimetric determination of microgram amounts of thiols. *Analyst*. 1958;83:670–672.
- (311) Rubanyi G, Vanhoutte P. Superoxide anions and hyperoxia inactivate endothelium-derived relaxing factor. *Am J Physiol Heart Circ Physiol*. 1986;250:H822–H827.
- (312) Gryglewski R, Palmer R, Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. 1986.
- (313) Moncada S, Palmer R, Gryglewski RJ. Mechanism of action of some inhibitors of endothelium-derived relaxing factor. *Proc Natl Acad Sci*. 1986;83:9164–9168.
- (314) Ignarro LJ, Byrns RE, Buga GM, Wood KS, Chaudhuri G. Pharmacological evidence that endothelium-derived relaxing factor is nitric oxide: use of pyrogallol and superoxide dismutase to study endothelium-dependent and nitric oxide-elicited vascular smooth muscle relaxation. *J Pharmacol Exp Ther*. 1988;244:181–189.
- (315) Förstermann U, Trogisch G, Busse R. Species-dependent differences in the nature of endothelium-derived vascular relaxing factor. *Eur J Pharmacol*. 1984;106:639–643.
- (316) Cocks T, Angus J, Campbell J, Campbell G. Release and properties of endothelium-derived relaxing factor (EDRF) from endothelial cells in culture. *J Cell Physiol*. 1985;123:310–320.
- (317) Rubanyi G, Lorenz R, Vanhoutte P. Bioassay of endothelium-derived relaxing factor (s): inactivation by catecholamines. *Am J Physiol*. 1985;249.
- (318) Gryglewski R, Moncada S, Palmer R. Bioassay of prostacyclin and endothelium-derived relaxing factor (EDRF) from porcine aortic endothelial cells. *Br J Pharmacol*. 1986;87:685–694.